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ABSTRACT 
This randomized, controlled, double-blind crossover study examined the effects of a 
preprandial, 20g oral dose of apple cider vinegar (ACV) on colonic fermentation and 
glycemia in a normal population, with the ultimate intention of identifying the 
mechanisms by which vinegar has been shown to reduce postprandial glycemia and 
insulinemia. Fifteen male and female subjects were recruited, ages 20-60y, who had 
no prior history of gastrointestinal (GI) disease or resections impacting normal GI 
function, were non-smokers, were non-vegetarian/vegan, were not taking any 
medications known to alter (glucose) metabolism, and were free of chronic disease 
including diabetes. Subjects were instructed to avoid exercise, alcohol and smoking 
the day prior to their trials and to consume a standardized, high-carbohydrate dinner 
meal the eve prior. There was a one-week washout period per subject between 
appointments. Breath hydrogen, serum insulin and capillary glucose were assessed 
over 3 hours after a high-starch breakfast meal to evaluate the impact of preprandial 
supplementation with ACV or placebo (water). Findings confirmed the antiglycemic 
effects of ACV as documented in previous studies, with significantly lower mean 
blood glucose concentrations observed during ACV treatment compared to the 
placebo at 30 min (p=0.003) and 60 min (p=0.005), and significantly higher mean 
blood glucose concentrations at 180 min (p=0.045) postprandial. No significant 
differences in insulin concentrations between treatments. No significant differences 
were found between treatments (p>0.05) for breath hydrogen; however, a trend was 
observed between the treatments at 180 min postprandial where breath hydrogen 
concentration was visually perceived as being higher with ACV treatment compared 
to the placebo. Therefore, this study failed to support the hypothesis that preprandial 
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ACV ingestion produces a higher rate of colonic fermentation within a 3 hour time 
period following a high-carbohydrate meal. Due to variations in experiment duration 
noted in other literature, an additional study of similar nature with an expanded 
specimen collections period, well beyond 3 hours, is warranted. 
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CHAPTER 1 
Effects of Vinegar on Colonic Fermentation and Glycemia 
A staggering two-thirds of the population in the United States is overweight 
or obese, and according to the US Centers for Disease Control (CDC) expert Dr. 
William H. Dietz this trend continues to spotlight as a leading preventable cause of 
death in the US population – second only in some surveys to tobacco use. A body 
mass index (BMI) of ≥ 25kg/m2 is a strong risk factor for developing one or many 
of the complications associated with obesity. One such complication is type 2 
Diabetes Mellitus (DM), a condition that materializes as a result of chronic glucose 
intolerance leading to partial or total insulin resistance, depending on the point of 
diagnosis and intervention. Others include heart disease, liver disease, and various 
cancers. 
The World Health Organization estimates that the number of cases of 
diabetes worldwide amounts to well over 346 million, with approximately 90% of 
these cases being type 2 DM. The American Diabetes Association (ADA) reports 
that there are almost 26 million people with type 2 DM in the United States alone. 
Also per the ADA, health care costs in the US associated with diabetes – such as 
medications, outpatient clinic visits and inpatient treatment regimens – are an 
estimated $174 billion annually. Many agencies and health professionals consider this 
situation unsustainable. Consequently, the focus is shifting in support of a more 
preventative care-approach, with “Healthy Lifestyles” or “Worksite Wellness” 
programs being implemented in the more progressive parts of the nation to improve 
health and fitness scores in attempt to minimize risk for developing adverse 
complications such as obesity and type 2 DM. 
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An integrative approach works well when diagnosing, treating and 
controlling cases of type 2 DM. As type 2 DM is a progressive disease it is possible 
to sustain partial glucose tolerance or even reverse the condition if it is detected and 
treated in its early stages before insulin resistance takes full effect. There are several 
studies that highlight the use of the oral medications, acarbose and metformin in 
managing blood glucose levels in those with prediabetes or glucose intolerance 
(Chiasson, 1996; Chiasson, 2002; Knowler, 2002; Scheen, 2003). Acarbose, an alpha-
glucosidase inhibitor, delays the digestion of carbohydrates by slowing the release of 
the chemicals responsible for breaking down carbohydrate into absorbable glucose 
molecules. Metformin, a biguanide, aids in more efficient removal of glucose from 
the blood by increasing insulin sensitivity in both muscle tissue and fat cells.  
Recent studies have shown that when these two drugs are used together in 
prediabetic populations, the progression rate for cases that develop into type 2 DM 
is reduced significantly. However, the United States Food and Drug Administration 
(FDA) has not approved the use of these two drugs for treatment without a formal 
diagnosis of type 2 DM (Mathur, 2011). Therefore, any acarbose or metformin 
prescription written for those with either early signs of insulin resistance or 
prediabetes would be considered “off-label” treatment. This is not illegal; yet in 
many circumstances this option is not available to individuals due to high costs or 
lack of health insurance coverage. Even if acarbose and metformin were approved 
for use the overall cost to manufacture and prescribe them would rise exponentially, 
adding to an already lofty spending budget. With an increasingly progressive outlook 
on healthcare taking shape, especially in the United States, there is a greater need for 
3 
a more conventional, more affordable method for controlling blood glucose at the 
prediabetes stage.  
Vinegar has a considerable history of serving a number of purposes – from 
use as a household cleaner and disinfectant, to use as an anti-hypertensive agent and 
anti-tumor agent. There are over 2,000 uses for vinegar registered in the Online 
Archive of American Folk Medicine. One of the more recent developments has been 
in studying its effectiveness in stabilizing blood glucose and insulin after meals. 
Several trials have been conducted examining dosage and timing, as well as the 
effectiveness of compounds similar to acetic acid (main constituent in vinegar) and 
compounds thought to mimic the biochemical pathways of acetic acid (Hunt, 1969). 
Results have shown that merely two to four teaspoons of vinegar (5% acetic acid) 
consumed prior to meals is associated with improved postprandial glycemia, 
increased satiety and weight loss (Johnston, 2010; Ostman, 2005; Kondo, 2009) – 
remarkably, all of which are associated with not only treating and managing type 2 
DM, but in counteracting obesity as well (Inzucchi, 2002). 
The mechanisms of action driving the success of vinegar as antiglycemic 
agent remain unclear. It is possible that acetic acid slows physical digestion to the 
point where carbohydrates are broken down at a rate much lower than normal, thus 
attenuating the postprandial glucose and insulin response. Another explanation may 
be that acetic acid inhibits disaccharidase activity; and as a result some forms of 
otherwise energy-dense polysaccharides flow undigested and unabsorbed through 
the small intestine and into the colon where they are fermented by bacteria – 
comparable to the transit of fiber and non-starch carbohydrate. If the latter 
speculation is even remotely accurate, then it may be useful to test breath hydrogen 
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to analyze colon contents and evaluate whether vinegar supplementation generates 
more colonic fermentation via excessive passage of undigested carbohydrate. 
If studies continue to spotlight vinegar – an inexpensive, highly accessible 
commodity – as a notable antiglycemic agent, then the search for a more 
conventional, more affordable method the biomedical community is conducting to 
find an adjunct to or stand-in for traditional medicine used to treat prediabetes and 
insulin resistance may be fulfilled. More studies will be needed to further assess and 
validate the efficacy of vinegar in controlling postprandial hyperglycemia and 
insulinemia, as well as to explore the mechanisms of action. However if vinegar 
continues to demonstrate as an effective antiglycemic agent, many people plagued by 
symptoms of insulin resistance and prediabetes may find cost-effective relief in 
vinegar supplementation and as a result annual healthcare spending may be greatly 
reduced to a more sustainable level. 
Purpose 
The purpose of this research experiment was to determine the effectiveness 
of an acute dose of 20g apple cider vinegar (ACV) on reducing postprandial glycemia 
and insulinemia in addition to producing an elevated hydrogen gas concentration in 
the colon in normal glucose-tolerant subjects in response to a high-carbohydrate 
load. While blood glucose and serum insulin measurements are instrumental values 
in determining the activity of ACV on carbohydrate metabolism, the main focus of 
this study lies with the hydrogen breath testing, which serves to validate or annul 
whether ACV disrupts normal, or expected, patterns of carbohydrate metabolism as 
otherwise indicated by lab values such as blood glucose and serum insulin. Variables 
that may have otherwise influenced blood glucose concentrations, such as exercise, 
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alcohol and caffeine intake, and the amount of carbohydrate intake prior to testing 
were controlled. 
Hypotheses 
H: 1 
The ingestion of ACV prior to a high-starch load will yield an increase in 
hydrogen levels in the colon over baseline measurements and over a 3-hour post-
meal period as compared to the control (no ACV ingested) as indicated by breath 
hydrogen measurement. 
H: 2 
The ingestion of ACV prior to a high-starch load will reduce postprandial 
glycemia and insulin levels compared to the control (no ACV ingested).  
Theoretical Perspective 
The primary research question driving this proposal was whether ACV given 
with a meal can prevent disaccharides from being digested and absorbed in an 
appropriate manner to where the presence of undigested, fermentable carbohydrate 
in the colon is significantly greater than without the administration of ACV, as 
detected by the hydrogen breath test. This postulation is based on documented 
evidence as follows: 
 Research has shown that acetic acid (ACV) demonstrates the capacity to 
attenuate the rise of postprandial blood glucose and serum insulin levels in 
both healthy and insulin-resistant individuals (Johnston, 2004; 2006; 2010). 
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 Research has shown that acetic acid (ACV) demonstrates the capacity to 
inhibit disaccharidase activity, specifically during post-translational 
processing, thereby yielding an antihyperglycemic response (Ogawa, 2000) 
 Recent studies have shown that increased colonic fermentation and 
subsequent gaseous production is directly proportional to presence of 
undigested starches (Nakamura, 2010). 
 Hydrogen breath tests have been examined, tested and confirmed to provide 
alveolar samples of accurate representation of the gas concentrations present 
the colon (Calloway & Murphy, 1968). 
 Since vinegar demonstrates the capacity to inhibit disaccharidase activity 
and/or block digestion and absorption of starch, it may be possible that 
some foods pass partially undigested into the colon when consumed with an 
appropriate amount of vinegar. Thus, it is logical to hypothesize that the 
ACV-treated subjects may yield a greater concentration of hydrogen in their 
colon, as evidenced by alveolar samples, than those who do not receive ACV. 
Definitions 
 Acetic Acid:  Primary constituent of the liquid vinegar, which is 
approximately 3-9% acetic acid by volume (Romero 1991). The molecular 
formula of acetic acid is C2H4O2.  
 Glycemic Index (GI): Classification of the glycemic response to 
carbohydrate-rich sources. A food is characterized as having a “high” GI if 
the metabolic response consists of a sudden and sharp increase in blood 
glucose and insulin followed by a rapid decrease in both markers; a food is 
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characterized as having a “low” GI if the metabolic response is a slower, 
more progressive increase in both markers with a subsequent slow decline. 
Reports show satiety ratings are higher with prolonged return of hunger 
following consumption of a “low” GI food. 
 Insulin Resistance (IR):  Impaired response at the cellular level by the 
hormone insulin to remove glucose from circulation. A person with fasting 
insulin of ≥18mU/ml (Laasko 1992) is considered to have IR. 
 Hydrogen Breath Test: Samples of alveolar air are collected via syringe from 
a bag of expired air and analyzed for content; alveolar air indirectly represents 
gaseous content and concentrations in proportion to what is present in the 
colon (Simren 2006). Methane and carbon dioxide levels are measured in 
addition to hydrogen with the particular instrument used in this study 
(BreathTracker™ SC; QuinTron Instrument Company, Milwaukee, WI). 
Assumptions 
 It was assumed that subjects complied with the following pre-testing dietary 
and exercise protocols: 
- Refrained from exercise and physical activity other than light 
household tasks or daily activities involving minimal exertion 24 
hours prior to each of their trial appointments; 
- Consumed a predetermined meal, high in carbohydrates (Subway 
meal), for dinner the nights before their trial appointments; 
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- Maintained a fasted state – no food or beverage, including gum – for 
at least 10 hours prior the time of their arrival for their trial 
appointments. 
 It was assumed that subjects provided accurate information on their medical 
history questionnaires. 
Limitations 
Possible limitations may include:  
 subject non-compliance with dietary and exercise protocols prior to each of 
the two trials 
 subjects enduring minor gastrointestinal dysfunction interrupting normal 
bowel habits during and around the two trials 
This study is confined only to those with normal glucose tolerance devoid of the 
need for hypoglycemic agents. 
Significance 
 Positive results obtained from this research experiment examining the 
effectiveness of ACV in producing greater concentrations of hydrogen gas in the 
colon as a direct result of increased colonic fermentation will be significant for 
current investigation of vinegar as an antiglycemic agent. Positive results will serve to 
further validate efficacy of vinegar as an antiglycemic agent, and research will 
continue to present and support vinegar as an alternate, non-pharmaceutical 
approach to treating glucose intolerance. Thus, long-term benefits may include a 
reduction of financial burden associated with standard prevention and treatment 
protocols for type 2 DM utilizing pharmaceutical intervention. Because this study is 
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limited to subjects demonstrating normal glucose tolerance further studies are 
needed to assess its effectiveness in the insulin-resistant and/or diabetic populations.
 10 
CHAPTER 2 
REVIEW OF LITERATURE 
Part I 
History of Vinegar 
The remedial powers of vinegar have been celebrated for over 10,000 years 
(Orey, 2000). The exact date of the earliest use of vinegar is unknown due its 
extensive history. Orey et al. (2000) suggests that one of the earliest documentations 
of vinegar use was made by the Babylonians, who produced vinegar by bacterial 
fermentation of date palm wine. The production of vinegar involves the 
fermentation of a starch to alcohol by yeast followed by conversion of alcohol to 
acetic acid by certain bacteria. Acetic acid is the main constituent of vinegar. The 
word “vinegar” originates from the French term “vin aigre” which means, “sour 
wine” (Webb, 2007).  
Properties of Vinegar 
Vinegar is a clear aqueous liquid, though the color may vary depending on 
the nature of the materials used in the manufacturing process. The pH of vinegar 
ranges from 2-3.5, depending on acetic acid content (Ebner, 2000; Webb, 2007). 
Vinegar typically has an acetic acid content of 40-180g/L (4-18%), and in the United 
States six of the more common types of vinegar, including apple cider vinegar, must 
be no less than 4% acetic acid, per manufacturing guidelines in the Federal Food and 
Drug Act of 1906 (Webb, 2007). Liquid acetic acid is a hydrophilic, carboxylic acid 
and has a chemical formula of CH3COOH. With regards to most vinegars density, 
viscosity, surface tension and freezing and boiling points are fairly similar to those 
values of pure distilled water (Ebner, 2000). 
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Production of Vinegar 
Vinegar production is a straightforward and simple process: ethanol is 
exposed to oxygen, and bacteria are responsible for aerobic conversion into the 
finished product. The amount of time required for production can range from one 
day to upwards of several months depending on the methods and materials used 
(Orey, 2000). Both the fermentation of carbohydrate to ethanol and the oxidation of 
ethanol to acetic acid are heat-yielding (exothermic) reactions (Webb, 2007). 
Orey et al. explains the general production process in detail. Any fermentable 
carbohydrate source – such as fruit, grain, whey, and molasses – is subjected to the 
addition of yeast, which yields alcohol. The aerobic bacteria acetobacter (genus of 
acetic acid bacteria) is then added to the new liquid and in the presence of oxygen 
the product is converted to acetic acid (acetification). Acetic acid content of vinegar 
is variable and dependent on the extent of the acetification process. Most vinegars 
for culinary purposes are in the range of 4-8% acetic acid, and most vinegars used for 
pickling and other commercial purposes are 12-20% (Fleming, 2001). The 
composition of vinegar is variable and is governed by the selection of the raw 
material, the nature of the yeast and bacteria used for fermentation, the acetification 
method, as well as the bottling, storing and aging process (Ciani, 1998; Tesfaye, 2002; 
Webb, 2007). 
Acetification methods vary, and despite technological advances that allow for 
greater production in a shorter amount of time, experts proclaim that a traditional, 
well-controlled, lengthy oxidation period produces better vinegar (Ward, 1996). The 
Orleans method embodies such practice (Webb, 2007). With this traditional method, 
acetobacters are positioned at the top of the liquid (exposed to the atmosphere), and 
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acetification of the ethanol is carried out in wooden casks. Over the course of several 
months to several years the product is rotated out into different casks during which 
time the product is well blended and ultimately thought to be of higher quality 
(Torija, 2009). Caligiani et al. (2007) examined different types of wood and wood 
thickness on acetification kinetics in traditional vinegar production and found that 
porosity of the wood and surface/volume ratio are important characteristics for 
successful yield in the lengthier acetification methods. 
In the shorter contemporary methods the acetifying bacteria are suspended 
in the middle of the liquid in the holding tank, while the ethanol is stirred constantly. 
Bubbles are generated at the bottom of the holding tank and pass by the bacteria 
colonies while rising to the top, thus allowing for a greater rate of oxygenation for 
faster acetification (Webb, 2007). While the finished product is available after only 
about a day, critics pass judgment on the lack of subtle flavors and fine distinctions 
otherwise demonstrated by vinegars produced with the lengthier, traditional methods 
(Orey, 2000). Orey et al. also suggests that vinegar produced by faster methods lack 
certain nutrients and enzymes. 
According to Webb et al. (2007), grape juice and apple juice both contain 
sufficient concentrations of the nutrients required for fermentation of sugar to 
alcohol, while other sources of starch often require supplementation with 
compounds such as nitrogen, phosphorus and potassium and may even require the 
addition of autolyzed yeast strains to facilitate proper growth of the appropriate yeast 
for the fermentation process. Thus grape and apple juices are ideal raw materials for 
vinegar production, as the equilibrium of nutrients and additives is not as challenging 
for producers to achieve and monitor. 
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Uses of Vinegar 
Recipes and concoctions have been handed down from generation to 
generation, perfectly preserved in their simplicity. There are over 2,000 uses for 
vinegar documented in the Online Archive for American Folklore Medicine (UC 
Regents, 2001). Since the early days, vinegar has commonly been accepted as an 
ingredient in food preparation and food preservation, a household cleaning product 
and a treatment for fungal infections and dandruff, and now research is targeting the 
potential of vinegar as an antiglycemic agent, an antihypertensive agent and even an 
antitumor agent (Johnston, 2006).  
Orey et al. (2000) explains how vinegar has been used throughout history for 
many purposes, especially in medicinal practice. Hippocrates, known as “the father 
of medicine” promoted the use of vinegar for treating wounds, burns and respiratory 
conditions due to his belief that vinegar held antibiotic and anti-inflammatory 
attributes. Labor workers in the 1700s and 1800s discovered that a mixture of 
vinegar and water gave them an extra boost in performance during their workdays, 
thus vinegar was dubbed the “first energy drink”.  
Vinegar has its place in legends; literature and popular media tout vinegar as 
an alleged “magical” therapeutic agent (limited supporting research) aiding digestion 
and weight loss, relieving muscle and joint pain, boosting the immune system, and 
treating head lice and nail fungus (Asala, 2000; Orey, 2000). According to legend in 
France (Norn, 2007), the “Four Thieves” robbed houses of deceased persons during 
the Black Plague outbreak without ever getting sick themselves. When caught and 
put on trial, the court granted freedom on the condition that they proclaimed their 
secret to avoiding infection. They came forward with a potion sold to them by a 
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medicine woman – which consisted of a mixture of garlic, herbs and sour red wine 
(vinegar).  
Part II 
Scientific Research and Vinegar 
 While limited scientific evidence is available to support many of the 
proclaimed therapeutic uses of vinegar, there are studies that have demonstrated 
some medicinal value of vinegar predominantly for diabetic-, cardiovascular- and 
cancer-related conditions. A growing number of researchers are conducting various 
new studies to further examine the potential of acetic acid, the main and most active 
constituent of vinegar, as an anti-tumor agent, an anti-glycemic agent, and anti-
hypertensive agent (Johnston, 2006). Other research is targeting its value as a 
nutritional supplement with particular interest in exploring polyphenol, antioxidant, 
vitamin and mineral content. Ebihara & Nakajima were the first to report on the 
anti-glycemic properties of vinegar in 1988.  
 Acetic acid, when exposed to standard base, is converted to acetate. Acetate 
is absorbed across the epithelium of the gastrointestinal tract. While the majority of 
acetate produced by base conversion or colonic fermentation is absorbed and 
subsequently excreted by the liver, some of it escapes into peripheral circulation 
(Pomare, 1985).  
It has been proposed that orally ingested acetic acid is effective in controlling 
postprandial glycemia, insulinemia and satiety (Johnston, 2010; Ostman, 2005; Hunt, 
1969; Brighenti, 1995). However, the mechanisms driving these changes in metabolic 
events are not clearly understood. One theory suggests acetic acid inhibits 
disaccharidase activity (Ogawa, 2000), converting otherwise absorbable carbohydrate 
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into resistant starch to pass undigested into the colon to be fermented. This prevents 
glucose from entering the bloodstream, thus attenuating the subsequent rise in blood 
glucose. Another possibility is that acetic acid slows gastric emptying, which projects 
a steadier rise and more prolonged fall in blood glucose and insulin. Liljeberg et al. 
(1998) credits organic acids, such as those found in sourdough bread, to delayed 
gastric emptying of a meal, which in turn improves glucose tolerance to starch. A 
third proposed mechanism is that acetic acid acts directly on enzymes responsible for 
cellular uptake of glucose into liver cells and skeletal muscle tissue (Fushimi, 2001). 
Brighenti et al. (1995) provides a fourth theory and credits the acidity factors of 
acetic acid for the 31.4% reduction in postprandial glucose response observed in 
their subjects after consuming vinegar with a high-starch meal. 
Several studies are outlined in the following sections that endorse significant 
findings with vinegar as they pertain to its noteworthy capabilities as a promising tool 
in the future of diabetes treatment and prevention. 
Acetic Acid as an Antiglycemic Agent.  In early studies, research was 
carried out to examine the antiglycemic effects of vinegar ingestion. The different 
forms of acetic acid, the dose-response relationship and the types of meals it might 
have an effect on were explored (Ebihara & Nakajima, 1988; Hunt, 1969; Johnston, 
2004; Liljeberg, 1998). Leeman et al. (2005) studied the effects of the temperature of 
potatoes at the time of consumption in addition to vinegar dressing supplementation 
on postprandial glycemia and insulinemia. In 13 healthy subjects they found a 
significant decrease in the glycemic index of potatoes served at 8°C – which equates 
to an increase in resistant starch content. Subsequently they noted a further decrease 
in glycemic index of the cold potatoes when served with vinaigrette dressing (acetic 
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acid content 6%). In the latter testing glycemic (GI) and insulinemic (II) indices of 
the meal were reduced by 43% and 31%, respectively in comparison to the GI and II 
of freshly boiled potatoes, no added vinaigrette. Glycemic response was measured by 
capillary blood glucose testing as well as serum insulin. 
Ostman et al. (2005) studied glycemic and insulinemic responses to a high-
starch meal (50g complex carbohydrate) with acetic acid supplementation in varying 
doses (18, 23 and 25mmol); results were significant for an inverse relationship 
between reduction in both glucose and insulin and higher doses of acetic acid. 
Postprandial satiety ratings were also assessed in this study, and results indicated 
significantly greater and more prolonged satiety in association with vinegar 
supplementation compared to placebo. It needs to be noted that satiety scores are 
subjective since they are self-reported responses. 
In another study, Johnston et al. (2004) were able to prove that vinegar 
reduces postprandial blood glucose and insulin levels in insulin-resistant (IR) 
individuals. Subjects with and without IR, as well as subjects with type 2 diabetes 
mellitus (type 2 DM) were given 4 teaspoons (20g) apple cider vinegar followed by a 
standardized, high-carbohydrate meal two minutes later. Serum insulin and glucose 
were measured by venous blood draw at 30 and 60 minutes. Within-subjects results 
were analyzed from the data collected and insulin sensitivity was increased by 34% 
(p=0.01) in those with IR but insulin sensitivity only increased slightly (19%; p>0.05) 
in those with type 2 DM. Among the controls, a significant reduction in insulin flux 
was seen (p=0.02). Johnston et al. suggested the physiological impacts of vinegar 
supplementation with regards to glycemic control are comparable to commonly 
prescribed medications such as metformin and acarbose. More studies will need to 
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be conducted to determine efficacy of vinegar as an antiglycemic agent especially in 
insulin-resistant populations. 
In 2005, Johnston & Buller examined the role of complementary foods on 
mealtime glycemia and satiety. In a randomized crossover study, which comprised of 
six total trial visits for each of 11 healthy subjects (separated by one week), peanut, 
vinegar or placebo supplements were given with each of two meals – one with a 
glycemic index (GI) of 81 and one with a GI of 48. Serum insulin and glucose were 
assessed at 30 and 60 minutes. Results showed that both the peanut and vinegar 
supplementation reduced glycemic response following both the high GI meal and 
the low GI meal by more than 50% (p<0.05). Johnston et al. suggests the 
mechanisms for the efficacy of vinegar is related to its supposed ability to increase 
cellular uptake and utilization of glucose by skeletal muscle and peripheral tissue as 
well as its ability to inhibit certain disaccharidase activity in the intestinal epithelium, 
as supported by previous research (Ogawa, 2000; Fushimi, 2001). Peanuts contain 
arginine, an amino acid known to enhance insulin production and excretion (Nesher, 
2002), which may offer an explanation of the efficacy of peanut supplementation in 
reducing postprandial glycemia. To examine satiety after each meal, subjects were 
instructed to record food and beverage intake for the remainder of the day after each 
visit. An insignificant reduction in caloric intake was reported following the meals 
(p=0.111) and no correlation was seen between peanut, vinegar or placebo and either 
of the higher- or lower-GI meals. This evidence is inconsistent with literature 
describing increased satiety ratings and decreased total daily consumption associated 
with intake of low GI foods and meals (Roberts, 2000). Limitations of this study 
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include a small sample size, limited time span of insulin and glucose recordings (only 
60 minutes), and self-reported scores used in analysis. 
In 2007, White & Johnston examined the effects of apple cider vinegar 
(ACV) on waking blood glucose concentrations in people with non-insulin 
dependent type 2 diabetes mellitus (type 2 DM). Over three consecutive days, nightly 
administration of 2 tablespoons ACV with 1 ounce of cheese effectively lowered 
blood glucose at waking compared to the placebo. Subjects who had fasting (waking) 
blood glucose levels greater than 7.2mmol/L prior to the study experienced a greater 
reduction than those who had reported fasting levels at less than 7.2mmol/L prior to 
the study (6% and 0.7%, respectively). They noted the work of Fushimi et al. (2001), 
who indicate in their studies that acetic acid alters hepatic and skeletal muscle 
metabolism, suggesting the changes in liver affecting the gluconeogenesis/glycolysis 
cycle leads to greater control in preventing the “dawn phenomenon” – a metabolic 
complication triggering greater-than-normal hepatic production and output of 
glucose in individuals upon waking (Monnier, 2007). 
In 2009, Johnston et al. examined the efficacy of vinegar in reducing 
glycosylated hemoglobin A1c (HgA1c) – a well-known indicator of long-term blood 
glucose control. Those with prediabetes and type 2 DM, in most cases, will have a 
HgA1c of 7% or higher. In this study, 27 subjects with type 2 DM who were not on 
insulin were randomly designated to one of three treatments, receiving either 1 
vinegar pill (control; 15mg acetic acid), 1 pickle (treatment; 700mg acetic acid), or 2 
tablespoons of vinegar (treatment; 1400mg acetic acid) twice daily with meals for 12 
weeks. Lipids, body weight and HgA1c were evaluated during this time. Results 
showed that those receiving the vinegar treatment experienced a decrease in HgA1c 
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of 0.16% units, while those with the pill treatment and the pickle treatment 
experienced an increase in HgA1c of 0.06% and 0.22% units, respectively. Lipids and 
body weight were not significantly different across the treatments nor did they differ 
from baseline measures.  
Johnston et al. (2009) noted that previous studies on type 2 DM populations 
have shown that dietary changes, specifically adopting a diet consisting of low-
glycemic index (GI) foods, can result in HgA1c levels ~0.30% units lower than those 
consuming a high-GI diet (Brand-Miller, 2003; Opperman, 2004). Meanwhile, studies 
on a standard diabetes drug, acarbose, show that it yields a decrease in 0.43% units 
on a 12-week treatment regimen (Fischer, 1998). These are interesting points and 
suggest that vinegar supplementation can yield comparable results to dietary changes 
and medication use with regards to blood glucose control. 
In 2010, Johnston et al. examined the effects of acetic acid on postprandial 
glycemia in four trials using subjects both with and without type 2 DM. They 
investigated timing, dosage and application of acetic acid and found that 10g (versus 
20g) of vinegar (versus acetic acid in the form of neutralized salts) administered 
during mealtime (as opposed to five hours prior to the test meal) significantly 
reduced postprandial blood glucose levels as evidenced by area-under-the-curve 
(AUC) calculations up to 120 minutes post meal. Johnston and colleagues also noted 
that the blood glucose response was not significantly reduced when subjects received 
vinegar with a test meal consisting of monosaccharides – suggesting that the 
mechanism by which acetic acid effects glycemia must be related to carbohydrate 
digestion (specifically polysaccharides).  
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Acetic Acid and Enzymatic Activity.  Ogawa et al. (2000) conducted an 
in-vitro study on human intestinal cell line Caco-2 to study the mechanisms by which 
acetic acid supplementation affects glycemia. Though the Caco-2 cells are derived 
from a colon carcinoma they effectively act like intestinal epithelial cells once they 
have undergone differentiation and polarization (Pinto, 1983) because they possess 
both glucose transporters and disaccharidases (Stein, 1996; Howell, 1992). Ogawa et 
al. induced chronic exposure (15 days) to various acids, including acetic, on the 
Caco-2 epithelium, which houses multiple disaccharides and hydrolases. The 
investigators examined maltase, trehalase, lactase, sucrase and other peptidases, as 
well as angiotensin-converting enzyme (ACE). They found that acetic acid 
suppressed sucrase, trehalase, lactase and maltase activity in the cultured Caco-2 cells. 
What they were not able to conclude, however, was that acetic acid supplementation 
inhibits glucose transport. Ogawa et al. used radioactive 3-O met glucose, a non-
metabolizable substrate to study influx during acetic acid supplementation, and 
found that both trans-epithelial electrical resistance (TEER – tightness of the 
intestinal monolayer; permeability decreases as tightness increases) cellular uptake of 
3-O-met glucose were no different from the controls.  
Ogawa et al. (2000) also explored the effects of acetic acid at the mRNA 
level, by using Northern Blot analysis to examine acetic acid supplementation and 
de-novo synthesis of the sucrase-isomaltase complex mRNA. The results were 
insignificant and they were not able to conclude that acetic acid influences 
transcriptional regulation of disaccharidases, which suggests that the action of acetic 
acid is carried out in the post-translational processing of the complex (Ogawa, 2000).  
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In a 2002 study Fushimi et al. found that post-exercise glycogen repletion 
was significantly enhanced in soleus muscle, but not in gastrocnemius muscle or in 
the liver, when rats were given a 2mL dose of 30% glucose/0.4% acetic acid solution 
after two hours of swimming, as compared to a 2mL dose of a 30% glucose solution 
without acetic acid. In this study Fushimi et al. also noted that acetic acid 
supplementation correlated with an increase in glycogen synthase I in soleus muscle. 
Henriksen et al. (1990) reported higher GLUT-4 transport protein content in soleus 
muscle than in gastrocnemius muscle, suggesting that soleus muscle has an innate 
capacity for greater glucose uptake. In a separate study by Takeuchi et al. (1993) 
post-exercise acetic acid supplementation alone (2.5%) had no enhancing effect in 
regard to glycogen repletion.  
In vitro, citrate has been found to reduce the activity of phosphofructokinase 
(PFK) (Newsholme, 1997), an enzyme involved in the conversion of glucose to 
pyruvate, otherwise known as glycolysis. Citrate is a compound formed in acetyl-coA 
metabolism, which is preceded by the conversion of acetate to acetyl-coA by acetate 
thiokinase (Ballard, 1972). Saitoh et al. (1983) observed that citrate/glucose 
supplementation is associated with enhanced post-exercise glycogen repletion 
compared to glucose administration alone.  
Qiu et al. (2010) examined the antioxidant capacity of vinegars, which have 
previously been demonstrated to contain high amounts of polyphenols and 
flavonoids (Alonso, 2004; Verzelloni, 2007). They confirmed that oat and rice 
vinegars, at various doses, demonstrated radical scavenging activity in vitro and 
significantly boosted the enzymatic activity of superoxide dismutase and glutathione 
peroxidase in vivo. Additionally they saw that levels of lipid peroxidase decreased 
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significantly in the rats given oat vinegar, which indicates that vinegar’s capacity to 
limit oxidative damage may be due to its ability to decrease lipid oxidation. They also 
were able to conclude that the ethyl acetate extract of oat vinegar expressed more 
types of phenolic acids and greater antioxidant capacity than rice vinegar.  
Honsho et al. (2005) studied the mechanisms behind the hypotensive effects 
of a vinegar-based beverage demonstrated in rats. When the recommended dosage 
was administered to the rats (3ml/kg) angiotensin I-induced pressor response fell 
from 57±2 to 45±7mmHg by the end of 60 minutes (p<0.05). A separate trial 
conducted by Honsho et al. revealed that the beverage caused a significant reduction 
in activity of angiotensin-converting enzymes. Their results suggest that hypotensive 
action of the vinegar-containing beverage can be explained by inhibition of the 
angiotensin-converting enzyme. 
Acetic Acid and Delayed Gastric Emptying.  Hunt et al. (1969) looked at 
the effects of nine different acids on gastric emptying rate in human subjects, 
including acetic acid and lactic acid. Their observations were that low molecular 
weight and high acid concentration decrease the rate at which gastric contents move 
into the duodenum. These findings suggest that acetic acid, at a molecular weight of 
60g/mol would be more effective at lowering gastric emptying rate than lactic acid, 
which has a molecular weight of 90g/mol. Liljeberg & Bjorck (1998) had results 
consistent with these observations, as they were able to show that the presence of 
acetic acid was associated with a delay in appearance of paracetamol (acetaminophen 
– used as a marker of gastric emptying/content absorption for this particular test) in 
the bloodstream whereas lactic acid was not, suggesting that acetic acid 
administration is related to a reduction in gastric emptying rate.  
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Hunt et al. (1969) also studied how active each of the acids were on gastric 
receptor effector system and postulated that since this activity was consistent among 
the nine acids in their study, the relationship between weight/acid concentration and 
effectiveness is likely to occur in pre-receptor events. They postulated that if the 
activities and events of secretin receptors are involved in gastric emptying rate, acetic 
acid, with its low molecular weight and high acidity, might have an inhibitory effect 
on the release of secretin. Secretin is responsible for neutralizing acids in the 
duodenum so contents may pass through at a pH range well tolerated by the rest of 
the gastrointestinal tract. 
Hlebowicz et al. (2007) worked with individuals with type 1 diabetes mellitus 
(type 1 DM) and identified the disadvantage of vinegar supplementation in this 
population. They discovered that vinegar taken with meals reduces gastric emptying 
rates even further in those who demonstrate type 1 DM-induced gastroparesis. This 
would greatly impact glycemic control with regard to insulin dosing and timing. 
Pharmaceutical Drugs Used for Glycemic Control and Preliminary Evidence 
of Acetic Acid as an Alternative or Complementary Form of Treatment 
 In a review article, Inzucchi et al. (2002) examines the different categories of 
oral antiglycemic agents and reviews the available literature on the efficacy of these 
particular drugs. They are able to conclude that with monotherapy, all major drug 
classes – biguanides, alpha-glucosidase inhibitors, thiazolidinediones (TZDs), and 
sulfonylurea (SU) and nonsulfonylurea (NSU) insulin secretagogues – act almost 
equally in improving glycemia and insulinemia in the same group of patients with 
non-insulin dependent type 2 diabetes mellitus (NIDDM). Inzucchi et al. praises the 
lack of hypoglycemia, improved plasma lipid concentrations and reported weight loss 
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associated with the use of metformin, a biguanide, and describes its popularity as a 
front-line medication for obese patients (UKPDS, 1998). They also comment on the 
disadvantages and adverse side effects associated with the use of TZDs, such as 
edema, weight gain, slow onset of action as well as the need for constant monitoring 
of liver function (LFTs). The others (alpha-glucosidase inhibitors, SUs and NSUs) 
are virtually equally effective however constant monitoring for hypo- or 
hyperglycemia and hypo- or hyper-insulinemia is required with the use of each in 
NIDDM populations.  
 Inzucchi et al. (2002) also examines and reports on the literature available 
describing the use of combination therapy. With combination therapy, two or more 
drugs with distinct mechanisms of action are prescribed to NIDDM patients, with 
the expectation that improvements in glycemic control will be achieved and 
potentially the patient may be able to receive lower drug dosing in select settings 
(Erle, 1999), as well as reductions in adverse side effects. Inzucchi et al. reports that 
no specific combination of major drug classes outperforms another in improving 
glycemic and insulinemic control or in preventing complications. If glycemic control 
is not achieved with the use of either monotherapy or combination therapy, or 
efficacy of said therapies begins to decline over time, Inzucchi et al. supports the 
notion of introducing insulin therapy either alone or in conjunction with the oral 
antiglycemic agents. 
 Metformin, the front-line drug of choice, has been studied extensively to 
reveal its short- and long-term benefits as an antiglycemic agent for those with 
NIDDM (Knowler, 2002). Metformin pharmacokinetics is described elsewhere in 
literature (Beckmann, 1971; Sterne, 1969; Hermann, 1979; Schafer, 1983). In 
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summary, metformin enhances post-receptor insulin activity in peripheral tissues 
such as muscle, and also puts a limit on hepatic production of glucose yet does not 
eliminate production altogether and thus hypoglycemia is not a common adverse 
effect. Bailey et al. (1992) notes that metformin is not only successful in reducing 
fasting blood glucose concentrations (~20% reduction), it is substantially more 
effective than other drugs in reducing postprandial glycemia in NIDDM patients 
(~45% reduction) (Campbell, 1995). 
Acarbose, another front-line drug, is an alpha-glucosidase inhibitor and its 
mechanism of action in improving glycemic control is the enhancement of insulin 
sensitivity. As a result acarbose improves postprandial cellular uptake of glucose and 
reduces postprandial blood glucose concentration; thereby reducing the strain on 
beta cells to produce additional, compensatory insulin (Van de Laar, 2006). Acarbose 
increases insulin sensitivity in those with type 2 DM and in those with impaired 
glucose tolerance (Chiasson, 1996). Acarbose has also been associated with a 
reduction in risk for coronary artery disease (CAD) (Shimabukuro, 2006). 
 Because the number of cases of prediabetes is increasing around the world, 
and in many cases it goes undiagnosed through progression to NIDDM, more focus 
is being shifted to medical interception at the early stages of this progressive disease 
due to the increased likelihood of disease reversal in the prediabetic phase (Chiasson, 
2002; Scheen, 2003). A diagnosis of prediabetes is made when fasting blood glucose 
is measured and recorded between 100 and 125mg/dL. Currently there is limited 
access to oral antiglycemic drugs for those with prediabetes, since use is considered 
“off-label” (Mathur, 2011); however they are being prescribed in some cases as there 
is evidence to support their effectiveness in insulin-resistant individuals (Van de Laar, 
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2006). Large-scale testing of antiglycemic drugs in this population has been 
conducted as a part of the Diabetes Prevention Program and the STOP-NIDDM 
initiatives. 
The purpose of prescribing oral antiglycemic drugs to patients with insulin 
resistance and NIDDM is to control their postprandial glycemia and insulinemia. 
Regardless of the mechanism by which these drugs may work, the results are 
consistent with blood glucose-lowering effects. As noted in the preceding section, 
vinegar may be considered another oral agent that decreases postprandial blood 
glucose. 
Part III 
Colonic Fermentation 
 The human colon is thought to be one of the largest, most densely populated 
ecosystems in the world (Meyer, 2009). Xu & Gordon (2003) reviewed available 
literature and determined that the colon is home to approximately 500-1000 different 
species of bacteria, which together weigh in the range of 100g to 1.5kg. Their 
metabolic activity, functions and effects on human health are all topics being 
thoroughly researched, and to date there is literature published on most of the 
species, a consequence of new analysis techniques targeting nucleic acids, 
proteomics, and metabolomics (Meyer, 2009).  
 While most material ingested orally is digested and absorbed proximal to the 
large intestine, what remains unabsorbed passes into the colon and becomes a 
fermentable substance. Bacteria begin the highly cooperative, anaerobic conversion 
of polymerized carbohydrates (further classified as either resistant starch or non-
starch polysaccharides) into energy (Nakamura, 2010), and byproducts such as short-
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chain fatty acids (SCFA), hydrogen and carbon dioxide are produced (Cummings, 
1987). Hydrogen and carbon dioxide, in addition to SCFA and its successors, acetate, 
propionate and butyrate all have an important impact on physiology and metabolism 
and are arguably beneficial to human health on a larger scale. Regular consumption 
of a high-resistant starch diet has been associated with a decrease in risk for bowel 
disease and cancer (Topping & Clifton, 2001). 
 Cummings & Englyst (1987) classified resistant starch into three groups: fully 
intact or partially milled grains; starch trapped in ‘granules’; and retrograded amylose. 
In common food items, only a small amount escapes small bowel absorption – about 
4% of meals, according to Flourie et al. (1988) – however the amount can reach up 
to 89%, as evidenced in the consumption of unripe bananas (Englyst & Cummings, 
1990).  
 End products of the fermentation of resistant starch include hydrogen and 
methane gases. To the knowledge of many researchers, methane-producing bacteria 
are only found in the colons of approximately 30-50% of the Western population at 
a detectable threshold (McKay, 1985; Nakamura, 2010). Methane-producing bacteria 
convert free hydrogen into methane (Nakamura, 2010). Methane and hydrogen can 
both be measured by breath sampling, and with the use of a traditional breath-
hydrogen analyzing instrument, nearly accurate assessment of the concentrations of 
the two gases in the colon can be successfully determined, and these values can in 
turn be used to gauge colon fermentation. 
The term ‘prebiotic’ was first defined by Gibson & Roberfroid in 1995 as 'a 
non-digestible food ingredient that selectively stimulates growth and/or activity of 
one or a limited number of bacteria in the colon, thereby improving host health'. It is 
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well established that the orally-ingested prebiotic compounds, such as resistant 
starch, non-starch polysaccharides, inulin, fructo-oligosaccharides, galacto-
oligosaccharides and lactulose, remain almost fully intact as they pass into the colon, 
and largely affect the composition and activity of colonic microbiota (Ellegard, 1997; 
Bosscher, 2009). Marketing of over-the-counter prebiotic supplements for the 
purpose of promoting overall health and well-being by generating a flourishing 
environment within the colon (Gibson, 2004) has recently become popular. On the 
other hand, use of prebiotic compounds for medical purposes, such as in research 
and as a means for diagnosing certain diseases and conditions, is also common.  
Products of Colon Fermentation 
Bacteria present in the gastrointestinal tract rely on their ability to exploit 
much of the content that passes through on its way to elimination in order to sustain 
its population. Energy and other products and byproducts are released during 
bacterial fermentation. What the fermentation process yields depends largely upon 
the type of bacteria, the substrate that is being converted, and what other 
compounds may be nearby for further processing. Technology has also allowed 
researchers to view the marked regional differences within the intestinal tract in 
regards to production (Cummings & Macfarlane, 1991). 
Short-chain fatty acids (SCFA) are the main products of bacterial 
fermentation. Their main constituents, acetate, butyrate and propionate – which 
account for 85-95% of the total SCFA in the colon – are usually found in all parts of 
the colon from the caecum, through the right, left and transverse colon and to the 
feces in varying concentrations (Cummings & Macfarlane, 1991; Cummings, 1979). 
Bacteria also create other acidic products when they ferment amino acids, such as 
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branched-chain fatty acids, isobutyrate, methylbutyrate and isovalerate, and they are 
also capable of producing the organic acids lactate and succinate (Cummings, 1987). 
In terms of gas production bacterial fermentation has the capacity to yield 
oxygen, nitrogen, hydrogen, carbon dioxide, and methane. Of these, methane, 
hydrogen and carbon dioxide have been studied extensively. Hydrogen results from 
the oxidation of formate or pyruvate. Formate can also be converted to carbon 
dioxide. It is less thermodynamically favorable to form hydrogen from formate than 
it is to form hydrogen from pyruvate, thus pyruvate is most essential to hydrogen 
metabolism (Cummings & Macfarlane, 1991). 
Hydrogenotrophs.  Certain species of bacteria generate hydrogen as a 
byproduct of oxidation-reduction reactions taking place during the conversion of 
substrates (Cummings & Macfarlane, 1991). There also exist certain bacteria that 
require this byproduct to support their own life cycles. The microbial utilization of 
the byproduct hydrogen is being thoroughly researched. There are three main groups 
of colonic bacteria that consume and dispose of hydrogen: methanogens, acetogens 
and sulfate-reducing bacteria (SRB). Collectively, they are known as the 
hydrogenotrophs. Though they are present in the colon in far fewer numbers than 
other fermentative bacteria, they play a very important, regulatory role in 
fermentation processes occurring throughout the entire colonic cavity. Their 
metabolism of hydrogen prevents hydrogen partial pressure from reaching the 
threshold restricting all fermentation (Nakamura, 2010).  
Methanogenesis.  Methanogens are a type of methane-producing bacteria 
present in the human colon. Most reduce carbon dioxide and four moles of 
hydrogen in a conversion sequence, which results in methane gas (Hedderich & 
 30 
Whitman, 2006; Dworkin, 2006); a process known as methanogenesis. Though 
characterization of methanogens found in the human colon is incomplete to date, 
five main isolates have been thoroughly researched and whole genome sequences 
have been established or initiated. These species have varying metabolic capabilities; 
for instance, one species, M.smithii is able to utilize carbon dioxide, hydrogen and 
formate for methanogenesis and also is capable of nonmethanogenic removal of 
methanol and ethanol (Samuel, 2007), whereas another species, M.stadtmanae is 
limited to methane production by reducing methanol using only hydrogen (Miller & 
Wolin, 1985). 
Sulfate Reduction.  Sulfate reducing bacteria (SRB) are also capable of 
hydrogen disposal in the colon, as they utilize four moles of hydrogen in 
dissimilatory formation of one mole hydrogen sulfide. For SRB, sulfate serves as a 
terminal electron acceptor for respiration. Per Muyzer & Stams (2008), electrons may 
be sourced from oxidation of sugars, amino acids, and one-carbon compounds such 
as methanol and carbon monoxide; additionally, electrons may be received when 
organic compounds, such as lactate, pyruvate, succinate, and SCFA are oxidized 
(Gibson, 1993). Thus, SRB do not rely entirely on hydrogen produced in vivo by 
other microbiota (Nakamura, 2010). Hydrogen sulfide, a highly toxic substance and 
potential threat to colonocytes and their metabolic function (Roediger, 1993), is 
completely dissociated to HS- and S2- in aqueous solutions. On average, humans do 
not retain hydrogen sulfide for very long, as it is readily absorbed in the gut mucosa 
or later expelled via flatus (Suarez, 1998).  
Acetogenesis.  Acetogens rely on mixotrophic activity to thrive in the 
human colon (Miller & Wolin, 1985). Acetogenic reduction is carried out in both 
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autotrophic and heterotrophic reactions, involving a variety of agents and substrates 
to facilitate growth and enumeration of acetogens. In a study by Miller & Wolin 
(1985), acetogen isolates grew poorly when exposed only to hydrogen and carbon 
dioxide, however the isolates rapidly co-metabolized hydrogen and carbon dioxide 
when glucose was added to their environment. Even though acetogens have versatile 
metabolic capacity, Christl et al. (1992) deems acetogenesis less important than 
sulfate reduction and methanogenesis with respect to hydrogenotrophic metabolism. 
Cord-Ruwisch et al. (1988) hypothesized that this is due to the latter two being more 
thermodynamically favorable than acetogenic reduction. 
Hydrogenotroph Symbiosis – Competition and Synergism.  
Competition exists among the hydrogenotrophic bacteria for the common, growth-
limiting substrate hydrogen (Cord-Ruwisch, 1988). Per Nakamura et al. (2010), there 
are two interactive models by which this competition is carried out: thermodynamic 
and kinetic. Using the Monod-type growth kinetics model, which is commonly used 
to explain microbial interactions in a substrate-limited environment, Lovley et al. 
(1982) determined that SRB have more favorable growth parameters than 
methanogens, especially when the colon has a high sulfur concentration. In addition 
to favorable thermodynamics whereby one bacterium out-competes another, a 
separate mechanism is explained by a minimum threshold model. Lovley et al. 
(1982), proposes that “organisms with higher substrate affinity and growth yield out-
compete others by maintaining the substrate concentration below the minimum 
concentration necessary for other organisms to conserve energy”. In a 1988 study, 
Cord-Ruwisch et al. determined that these thresholds are as follows: 10-20ppm of 
hydrogen for SRB, 30-100ppm for methanogens, and 400-950ppm for acetogens.  
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A limitation of these proposed mechanisms by which competition exists in 
the human colon is that it is assumed a stable, idealized environment with adequate 
nutrition and space in which all species are present unanimously exists perpetually. 
On the contrary, each and every human colon environment differs greatly from one 
another, with significant variability in available nutrients, pH, microbial diversity, 
microbial activity, anatomical structure, host health and much more. 
Dietary Effects on Microbial Environment of the Colon 
 There have been many studies conducted examining the main dietary 
substrates common in the Western diet thought to be available for fermentation by 
bacteria in the gut. Englyst et al. (1988, 1989) determined that approximately 8-18g 
of non-starch polysaccharides originating from all plant foods pass into the colon for 
bacteria to ferment on average each day. Cummings & Englyst (1987) saw that 
starchy food sources contributed 8-40g per day for colonic fermentation, in the form 
of resistant starch. Hosoya et al. (1988) noted that in the cases of individuals with 
lactase-enzyme deficiency, 2-10g of un-hydrolyzed, unabsorbed lactose sugars get 
passed into the colon for fermentation each day. Cummings & Macfarlane (1991) 
summarized the rest of the possible substrates contributing to colonic fermentation 
from various studies in their review article to include oligosaccharides, pancreatic 
enzymes, dietary protein, mucus, sloughed epithelial cells and other gut secretions. 
It has been postulated that diets rich in sulfate-containing foods, such as 
processed bread, nuts, dried fruits, vegetables, and fermented drinks such as beer 
contribute to a greater colonic production of hydrogen sulfide (Christl, 1992). The 
consumption of meat may also increase the production of hydrogen sulfide, 
according to a study by Magee et al. (2000), who explained that SRB utilized sulfur 
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substrates from sulfur-containing amino acids at a greater capacity than sulfur 
substrates from dietary sources of inorganic sulfate such as those mentioned 
previously.  
 In terms of dietary impact on methanogenesis within the colon, the research 
is limited and controversial. van Munster et al. (1994) showed that consumption of 
resistant starch increased methane excretion in habitual methane-producing 
individuals, but noticed that hydrogen excretion did not increase significantly in these 
individuals. They also found that the concentration of methane gas did not increase 
significantly in habitual non-methane-producing individuals after the meal, whereas 
hydrogen gas concentration did increase significantly. Levitt et al. (2006) also 
witnessed the latter events in their own study with similar methods and objectives.  
van Munster et al. (1994) suggests the lack of methane excretion does not appear to 
be due to dietary influences but to differences in colonic bacterial composition 
instead. They also speculated that the insignificant rise in hydrogen excretion in 
methane-producers after the meal challenge may be largely due to the fact that 
methanogens channel hydrogen for methane production, whereby decreasing free 
hydrogen concentration and thus resulting in a reduced amount detected by breath 
tests.  
 There is great interest in the study of prebiotics and their effects on intestinal 
function, metabolism and microbiota. The roles of prebiotics such as inulin-type 
fructans and polyphenols have a captive audience outside of the research community 
as recent marketing strategists have targeted the consumption of these compounds 
for improvements in gut health. As Bosscher et al. (2009) explains in a review article, 
polyphenols are derived from plant-based compounds such as esters, glycosides, and 
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polymers which, according to Manach et al. (2004) must be hydrolyzed in the gut to 
release the polyphenolytic constituents, namely phenolic acids, flavonoids (flavones, 
isoflavones, flavonones, flavanols and anthocyanidins), stilbenes and lignans. These 
all have been shown to house anti-inflammatory and anti-oxidative properties. Foods 
such as tea, soy, wine, cacao, fruits and certain vegetables contain complex mixtures 
of polyphenols (Manach, 2004). Bosscher et al. (2009) emphasizes the need for and 
the importance of future studies on the microbial metabolism of these compounds 
and, in return, what effects the metabolites might have on microbial composition 
and existence.  
 Inulin-type fructans are naturally occurring oligosaccharides that house plant 
energy reserves. Yet, they are recognized in the human gastrointestinal tract as un-
absorbable carbohydrates in the form of non-starch polysaccharides or resistant 
starch (Cook & Sellin, 1998). Ellegard et al. (1997) has shown that greater than 90% 
of ingested inulin passes into the colon almost fully intact and unabsorbed, where it 
is subsequently targeted by the microbiota for consumption and conversion to 
organic acids such as short-chain fatty acids (SCFA) and lactate, as well as gasses 
such as hydrogen, methane and carbon dioxide, and other bacterial biomass 
(Bosscher, 2009; Nakamura, 2010; Cook & Sellin, 1998; Ellegard, 1997). SCFA and 
lactate serve as energy sources for the host (Bosscher, 2009). Increased daily 
consumption of compounds such as soluble fiber that evade absorption proximal to 
the colon leads to greater production of organic acids by colonic microflora, and 
Cook & Sellin (1998) highlights the research supporting the wide array of health 
benefits associated with SCFA in humans independent of the microbial community 
in the colon. 
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Part IV 
Measuring Intestinal Gas  
Mammalian cells are not capable of producing hydrogen or methane gases; 
therefore the source of these gases has long been considered to be the product of 
microbial fermentation taking place within the anaerobic environment of the 
intestinal tract (Levitt, 1969). Rectal tubes or probes inserted for gas collection are 
not always practical – or comfortable for the patient – in every setting; they are 
mostly used for research purposes. Therefore, it is important to acknowledge the 
research on endogenous absorption, transport and capillary exchange of hydrogen, 
methane and carbon dioxide (McIver, 1926; Nielson, 1961; Calloway & Murphy, 
1968; Levitt, 1968; Newman, 1974). These gases readily diffuse down concentration 
gradients and pass into plasma, where they are directed by flow pattern to the lungs 
and again cross another membrane into alveolar air (Simren & Stotzer, 2006).  
Different methods of expired-air collection are used for research and medical 
purposes to assess the different gases gut bacteria may be producing, and at what 
rates and concentrations. The collection apparatus can be as simple as a plastic bag 
attached to a mouthpiece, and a syringe with which to draw contents from the bag 
(through a hole in the side of the mouthpiece) as the patient exhales into it. Breath 
testing is a useful tool in that it is an efficient, non-invasive, cost-effective method of 
gas measurement, and it is practical in many settings for gathering multiple sequential 
samples for continuous monitoring of the course of a disease or a response to 
treatment.  It is also not pertinent that a subject have adequate pulmonary function 
in order to obtain accurate results to the same degree with which other samples, like 
urine, might rely on good renal function (Calloway & Murphy, 1968). 
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There are other ways to measure intestinal gas, though no gold standard tool 
or method has been determined universally. In Australian literature, Eisenmann et al. 
(2008) claims the hydrogen breath test may be regarded as the most accurate means 
of testing, though standardization and interpretation of results, they explain, remain 
underprovided or incomplete. Another method is the use of 14Carbon-labeled CO2 
(14CO2) and infrared gas analysis, whereby continuous measurement of exhaled 
14CO2 following ingestion allows for development of mathematical equations and 
models explaining curves derived from the data collected (Tolbert, 1956).  
Cummings & Macfarlane (1991) have determined that as much as 65% of 
gases (hydrogen, methane and carbon dioxide) produced in the colon is released in 
expired air at gas production rates of up to 200ml/d; at 400ml/d or greater the 
percentage falls to 20%, resulting in an estimated average of 51% total gas 
production excreted in the breath.  
Hydrogen Breath Testing 
  The ability to detect hydrogen gas production in a breath test is based on the 
assumption that all hydrogen is produced endogenously by hydrogenotrophic 
bacteria living in the gut who rely on defective sugar absorption to carry out 
anaerobic fermentation (Calloway, 1966; Simren & Stotzer, 2006; Levitt & 
Ingelfinger, 1968; Newman, 1974). Alveolar air is representative of the hydrogen 
concentration present in the gut, as hydrogen – along with CO2 and methane – is 
absorbed into the bloodstream and brought to the lungs for capillary exchange and 
subsequent expiration. Breath testing is used to study the pathophysiology of medical 
conditions such as small intestine bacterial overgrowth, carbohydrate malabsorption 
(fructose, lactose, sorbitol, fructose-sorbitol and zylitol tolerance tests as well as 
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glucose- and lactulose-load tests; Eisenmann, 2008) and other gastrointestinal 
disorders. 
 Nielson (1961) was the first to establish that breath sampling was a feasible 
means of revealing certain gas profiles (such as hydrogen) found in flatulence. His 
theories were upheld as he observed that a rise in his patients’ breath hydrogen 
concentrations, as determined by gas chromatography, correlated well with their 
claims of increasing abdominal discomfort. Calloway (1966) also confirmed in her 
findings that breath hydrogen measurements were correlated with abdominal 
symptoms, and further determined that breath gas concentrations were substrate-
related. 
Levitt & Ingelfinger (1968) were the first to determine approximately how 
much of the total hydrogen produced in the gut is represented in a breath sample. In 
their study, nine subjects had tubes placed into both their small intestine and rectum, 
and they proceeded with a lactose challenge. A 60mL bolus of lactose was 
transplanted into the small intestine, while the subsequent outflow of gas was 
measured via the rectal tube. The researchers then took breath samples at six-minute 
intervals. They found that only approximately 14-16% of the total hydrogen gas 
produced in each individual as measured via the rectal tube was represented in the 
breath. 
Preparation for the Hydrogen Breath Test.  Muir et al. (1995) 
prescreened subjects for hydrogen production prior to enrollment into their study on 
colonic fermentation and resistant starch. Once enrolled they instructed their 
subjects to abstain from alcohol consumption and heavy exercise the day prior to 
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testing, and also instructed them to consume minimal amounts of fiber-containing 
foods after 1400 hours on the day before. 
Eisenmann et al. (2008) has outlined necessary preparatory guidelines for the 
patients to follow prior to taking a hydrogen breath test in a recent comprehensive 
review on the implementation of such tests. Their recommendations are as follows: 
Patients abstain from fibrous foods and beverages the day before the test, especially 
milk, fruit juice, leeks, onions, garlic and cabbage; the dinner meal in the evening 
before the test should contain little or no fiber; and the patient should not eat, 
smoke, or chew gum within twelve hours of the test, and water is all that is allowed 
in the following hours leading up to the test. Eisenmann et al. (2008) discredit the 
common myth that one must not brush their teeth prior to the test due to possible 
swallowing of sorbitol or zylitol in certain toothpastes; in fact, they claim that not 
brushing teeth may cause a false reading in breath hydrogen due to the possibility of 
bacteria present in the mouth. Muir et al. (1995) also supports the use of mouthwash 
prior to breath sampling as a part of proper test preparation. 
Contraindications for Hydrogen Breath Testing.   Eisenmann et al. 
(2008) describes the following contraindications for performing a hydrogen breath 
test in patients: if a patient has a high risk of hypoglycemia; if a patient has a 
hereditary intolerance to fructose; if a patient has had a colonoscopy, irrigoscopy, or 
fluoroscopy of the small bowel, if the patient has been on antibiotics, or if the 
patient has used an enema at any point in time in the previous four weeks. Patients 
with known fructose intolerance should not be subjected to a high fructose load due 
to the high risk of hypoglycemia to follow. Per Eisenmann et al., the bowels and 
microbiota need at least four weeks to recover from the cleansing methods used in 
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preparation for any of the previously described procedures, and a patient must 
produce three normal bowel movements to be considered a candidate for the 
hydrogen breath test. If a patient has an ileostomy, they are not suitable for hydrogen 
breath testing (Eisenmann, 2008). 
 Hydrogen Breath Testing in Research and Medicine 
 Levitt et al. (1969) examined the production rates and production sites of 
endogenous hydrogen gas. A multilumen tube was used to determine basal hydrogen 
production and subsequent production after an infusion with fermentable substrate 
(2g lactulose) in both a normal population and a patient population with small 
intestine bacterial overgrowth. There was no basal production of hydrogen in any 
region of the intestinal tract. After treatment with 2g lactulose it was reported that 
hydrogen was produced almost entirely in the colon in the normal population. In the 
population with small intestine bacterial overgrowth hydrogen production was seen 
in all regions but with 40 times greater concentration present in the colon than seen 
in the normal population after treatment. He also determined that the rate of 
production was as high as 1.5ml/minute after 2g lactulose was given. In breath 
testing his patients he found that approximately 21% of the gases that were produced 
in the bowels was present in the breath samples, and that this shared a linear 
relationship in concentration over time. An earlier study determined breath hydrogen 
concentration represents only about 13% of colon hydrogen concentration (Levitt & 
Ingelfinger, 1968). 
Chenoweth et al. (1972) used the hydrogen breath test to measure gas 
production in those with lactose intolerance. They determined that hydrogen 
production was dose-dependent in certain individuals when it was noted that 
 40 
subjects who tolerated 0.5g/kg lactose, as evidenced by an insignificant rise in breath 
hydrogen (p>0.05), did not tolerate lactose dosed at either 1.0g/kg or 1.5g/kg, as 
evidenced by a very significant rise in breath hydrogen. Chenoweth acknowledged 
inter-human variability yet concluded that abnormal breath hydrogen of greater than 
20ppm recorded in response to a 0.5g/kg dose of lactose was adequate to diagnose 
lactose malabsorption.  
Bond & Levitt (1972) found that post-gastrectomy patients who showed 
symptoms of diarrhea produced abnormal breath hydrogen results in response to 
100g glucose challenge. Those patients without diarrheal symptoms and normal 
subjects both showed breath hydrogen concentrations within normal limits. It has 
been widely observed that patients with diarrhea as a result of small intestine 
bacterial overgrowth – post-gastrectomy or not – consistently produce hydrogen in 
abnormal concentrations following lactulose (Levitt, 1968; 1969) or glucose (Bond & 
Levitt, 1972) challenges. According to Simren & Stotzer (2006) the hydrogen breath 
test is the most common tool used in diagnosing small intestine bacterial 
overgrowth. 
 In his review A. Newman (1974) highlights the potential for future 
application of the breath hydrogen test in revealing the carbohydrate malabsorption 
properties of certain drugs. Oxyphenistatin, phenolphthalein (Hand, 1966) and 
biguanides (Arvanitakis, 1974) have been found to have inhibitory effects on 
intestinal glucose absorption. Newman also pointed out the potential application of 
breath testing in describing isomaltase, trehalase, and sucrase deficiencies. 
 Many studies have looked at gas production in patients with gastrointestinal 
disease, in attempt to gain insight on both microbial environments and 
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malabsorptive characteristics within patient populations. Bjorneklett et al. (1983) 
failed to identify a single methane producer in their group of 28 patients with 
Crohn’s ileitis. Peled et al. (1987) observed methane production in only 6.1% of 
patients with Crohn’s and in 31.4% of patients with ulcerative colitis. McKay et al. 
(1985) noticed methane production in 13% of Crohn’s patients and in 15% of 
ulcerative colitis patients. These three studies formerly mentioned noted methane 
production in 50% or more of their control populations, who were disease-free. 
Pimentel et al. (2003) compared methane production to hydrogen production in 
patients with Crohn’s disease, ulcerative colitis, and irritable bowel syndrome (IBS).  
In this study all patients were given an initial lactulose dose followed by breath 
testing. It was reported that 76 out of 78 IBS patients produced hydrogen alone and 
the remaining two had both gases but methane was the predominant gas by volume, 
that 47 of 49 patients with Crohn’s disease produced hydrogen alone, and that all 29 
patients with ulcerative colitis produced hydrogen alone. Nakamura et al. (2010) 
attributed possible affected intermediate metabolic processes of pathophysiological 
correlates or traits of host origin (such as blood flow, tissue oxygen tension and 
epithelial integrity) to the consistent, marked reduction in methanogenesis in patients 
with gastrointestinal disease as seen throughout these studies; though they note that 
more research needs to be done in this area to better understand this occurrence. 
Gilat et al. (1978) studied bacterial growth under antimicrobial regimens and 
the effects on breath hydrogen testing. Three groups of patients were used – patients 
being prepped for gastrointestinal surgery with antibiotics and multiple enemas, 
patients being prepped for a colonoscopy with laxatives and enemas, and thirdly the 
aforementioned patients examined under control conditions. Immediately after their 
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scheduled procedures, the surgically prepped patients were given a formula 
containing lactulose and breath samples were taken every 30 minutes for 4.5 hours 
afterwards. In the control trial, the subjects fasted overnight and then proceeded 
with the same protocol. The results of the control trial were consistent in 44 out of 
the 55 subjects, with an umbrella-shaped curve that peaked at 2.5 hours. Eleven 
subjects had insignificant hydrogen production, plotting more than two standard 
errors below the mean. Elevated hydrogen at baseline was reported in four subjects 
and their results were removed from analysis. The results from those receiving the 
colonoscopy prep were also consistent with marked depression significant at all 
points after 30 minutes (p<0.05). However among those receiving the surgical prep, 
their results were much less depressed and had almost no instances of significant 
difference from the control at any point in time except at the 2-hour and 2.5-hour 
marks. They concluded the cleansing of the colon by enema and laxative use 
significantly suppresses hydrogen production after treatment with lactulose, likely 
due to the low bacterial count remaining in the colon after the mechanical flushes. 
Paired antibiotic and enema use, on the other hand, does not reduce microbial 
production of hydrogen after treatment with lactulose to the extent as previously 
described; the more variable results happen for reasons unknown. The authors do 
note that in a similar study conducted by Murphy & Calloway (1972) the antibiotic 
neomycin also had a variable and unremarkable impact on hydrogen production in 
flatus, following the ingestion of beans. In his review Newman (1974) shared his 
opinion on the matter in that it is worrisome that bowel surgery patients are being 
prepped with antibiotics that allow the production of hydrogen, which is a clear 
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indicator of the presence of bacteria, since these open-cavity procedures must be 
carried out in a sterile environment. 
There are a few studies emerging on the topic of gut health in relation to 
body weight and obesity. In a review article Nakamura et al. (2010) highlight new 
research suggesting the existence of an array of possible host and microbial 
mechanisms that impact energy metabolism. Evidently there may be a link between 
interspecies transfer of hydrogen and energy homeostasis that leads to an increase in 
fermentation efficiency as well as an increase in energy extraction from dietary 
polysaccharides. Samuel & Gordon (2006) have found that certain pairs of 
hydrogenotrophs capable of interspecies gas exchange are more prone to increasing 
adiposity within the host than other pairs. Turnbaugh et al. (2006) studied the 
microbial species Archaea, which house specific genes that program them for 
enhanced performance in the breakdown of polysaccharides, and found that obese 
mice had a greater abundance of this species in their gut than their lean littermates. 
They hypothesized that the transfer of hydrogen between bacterial and archaeal 
species is largely responsible for more efficient uptake of short-chain fatty acids from 
the gastrointestinal tract in overweight individuals. The research in this area is limited 
and more studies should be carried out in order to determine the origin of these 
microbial species and whether their existence precedes the onset of obesity 
(suggesting need for genetics research) or if obesity precedes their appearance in the 
gut. 
Interpretation of Hydrogen Breath Tests 
Eisenmann et al. (2008) claims there are three main factors vital to the 
interpretation of hydrogen breath tests: One, the hydrogen value obtained from 
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exhalation; two, the onset of physical reported symptoms; and three, fluctuations of 
these two parameters during the test contingent upon time elapse. There are certain 
qualifications for normal/negative and abnormal/positive breath results and they are 
outlined in the following sections. Simren & Stotzer (2006) established that end-
expiratory breath samples for diagnostic purposes are collected three hours 
postprandial. 
Normal, or negative results are generally received as little or no fluctuation 
from baseline measurements. Per Eisenmann et al. (2008), persistent recordings 
±5ppm from baseline measurement is indicative of normal absorption of the test 
substance. Eisenmann et al. also mention that if a patient shows insignificant results 
yet voices any physical discomfort during the test period, the test analyst must 
consider the possibility that the patient might be a non-producer of hydrogen. The 
possibility of a false-negative reading must also be considered; hidden variables may 
include a slow transit time where the contents simply did not reach the colon within 
the timeframe of the test period. Though it is generally accepted that it takes around 
90 minutes for unabsorbed substances to reach the large intestine, readings up to 180 
minutes may be considered, and if necessary, patients may be sent home with 
documentation materials to record “rumbling, bloating or diarrhea” later on in the 
day (Eisenmann, 2008 p.4). 
Abnormal, or positive results are generally received as concentrations of 
greater than 20ppm above the baseline measurement recorded at any given point 
after treatment (Metz, 1976; Eisenmann, 2008). Beyond this, Eisenmann et al. (2008) 
differentiates malabsorption from intestinal intolerance of a test substance 
respectively by absence or presence of physical symptoms, paired with the rise in 
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breath hydrogen. If a patient returns results greater than 10-20ppm over baseline 
within 30 minutes it may be possible they have small intestine bacterial overgrowth 
(Rhodes, 1979), and in the event of another peak seen after 60 minutes, with 
abdominal discomfort, it may be almost certain that this patient has small intestine 
bacterial overgrowth with an intact ileo-cecal valve (Eisenmann, 2008). If a patient 
returns a reading of greater than 20ppm within 30-60 minutes and shows a continual 
rise over time, it may be possible that the patient has small intestine bacterial 
overgrowth (Rhodes, 1979) and is experiencing initial “backwash” of stool traveling 
back up through the ileal-cecal valve from the cecum likely caused by colonic 
pressure and gas buildup; the remaining incline occurs as a result of further test-
substance intolerance if physical symptoms are present, or malabsorption if 
symptoms are absent (Eisenmann, 2008). 
Simren & Stotzer (2006) discuss the glucose-load test, and they affirm that it 
is very rare for glucose to escape digestion in the proximal small intestine and pass 
into the colon (Sellin & Hart, 1992). Proximal small intestine bacterial overgrowth 
may be a permissible diagnosis if breath hydrogen concentrations rise 10-20ppm 
over baseline after a glucose load. Simren & Stotzer also offer explanations for the 
incidence of a high fasting breath hydrogen concentration, which are that either the 
patient has small intestine bacterial overgrowth, that the patient has very slow bowel 
transit time (Corazza, 1990), or that the patient did not follow guidelines of 
consuming a low-fiber diet the day prior. Eisenmann (2008) suggests that another 
possible confounding influence is un-brushed teeth prior to testing, as bacteria 
residing in the mouth may affect the readings of the breath hydrogen test and be 
responsible for an erroneously high read. 
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Muir et al. (1995) collected breath samples from their subjects every 30 
minutes over the course of 16-18 hours for breath hydrogen concentration analysis 
in their study on colonic fermentation of resistant starch (RS). They observed a peak 
in breath hydrogen concentration 6-8 hours after a high-RS breakfast meal was 
consumed, and also reported that the greatest difference in breath hydrogen 
concentrations between high-RS and low-RS treatments occurred at 27 hours after 
the first test meal was consumed, where the high-RS diet was associated with 
significantly greater production of breath hydrogen. 
Caride et al. (1984) compared the use of a scintigraphic method against the 
breath hydrogen test (acting as the standard) in determining small intestine transit 
time following an oral dose of lactulose. The mean transit time in 20 individuals as 
determined by interval hydrogen breath testing was 75.1 ± 8.3 minutes (mean ± 
SEM) and the mean transit time as determined by the scintigraphic method was 73.0 
± 6.5 minutes. These values were similar (p<0.05), and thus deemed both methods 
accurate interpreters of gastrocecal transit time. 
Limitations of the Hydrogen Breath Test 
Several studies conducted using breath tests have come through with 
inconsistent and controversial findings. Collectively they point out a number of 
common limitations and variables that exist to create a wide margin of error for data 
collection and interpretation of breath tests.  
Metz et al. (1976) saw that the hydrogen breath test failed to detect what a 
jejunal culture aspirate confirmed was small intestine bacterial overgrowth in four 
out of twelve patients. To explain this occurrence they entertained the possibility that 
the bacteria present in these four subjects did not produce sufficient hydrogen gas 
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for detection in the breath. They also used a third method, a 14C-glycine-cholate 
breath test (14C-G.C.) which was developed specifically for the detection of certain 
types of bacteria in the small intestine that deconjugate bile acid. While each of the 
breath tests diagnosed 8 out of 12 patients, and 5 patients with positive results from 
both, the breath tests combined correctly diagnosed 11 of the 12 patients. In their 
conclusion they suggested the use of two breath tests for more accurate and more 
cost-effective diagnosis of small intestine bacterial overgrowth.  
 Corazza et al. (1990) compared the sensitivity and specificity of jejunal 
cultures against breath testing in their abilities to diagnose small intestine bacterial 
overgrowth in 77 human subjects. They determined that testing cultures obtained via 
tubing placed up into the jejunum was far more sensitive and specific than breath 
testing in correctly assessing whether or not the subjects had small intestine bacterial 
overgrowth. However when subjects were prepped separately with oral glucose or 
lactulose, hydrogen breath testing showed lower sensitivity at 62% and 68% and 
lower specificity at 83% and 44%, respectively. 
 Maung et al. (1992) examined the hydrogen production of enteric bacteria 
when exposed to lactulose in vitro. Jejunal aspirates were taken from 19 children 
thought to have small intestine bacterial overgrowth. The samples were incubated 
with lactulose, and hydrogen gas production was closely monitored. It was observed 
that while certain bacteria produced hydrogen at concentrations greater than 
100ppm, there were just as many bacterial species that did not produce any 
significant amount of hydrogen in vitro. Thus it was determined that when testing 
for small intestine bacterial overgrowth it is important to consider that individuals 
with a flat breath hydrogen response may contain enteric bacteria incapable of 
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producing hydrogen. It is important to note that while small intestine bacterial 
overgrowth often results from bacteria in the large intestine moving up into the small 
bowel – thus presenting researchers with a diverse spectrum of species to account 
for much of the intestinal flora – this study did not sample aspirates from the large 
bowel alone, and therefore the findings, while significant for the small bowel, cannot 
be generalizable to the entire intestinal tract. 
 Other studies have assessed the sensitivity and specificity of hydrogen breath 
tests in diagnosing small intestine bacterial overgrowth. Simren & Stotzer (2006) 
speculated on the matter and supposed that, sensitivity aside, such low specificity in 
comparison to other methods such as jejunal aspiration and culturing over time may 
lead to reservations about the usefulness of breath testing for such purposes. They 
emphasize the need to use these tests in a wise manner, and to use multiple methods 
when testing specimens if available. 
 It should be note that some people are non-producers of hydrogen gas – that 
is, their colonic environment does not house hydrogenotrophic bacteria in sufficient 
quantities that are collectively capable of producing a sufficient amount of hydrogen 
gas to meet the minimum detection threshold of the hydrogen breath test. This event 
has been observed in several studies, though in these following cases the prevalence 
of non-producers was very few; nevertheless, their existence should be noted. Bond 
& Levitt (1972) saw that two out of their 42 subjects did not produce hydrogen, 
Levitt & Donaldson (1970) saw that two out of their 55 subjects did not produce 
hydrogen, and Metz et al. (1976) had one such subject out of 52. 
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Methane Production 
 While hydrogen production in the colon is universal in nearly all humans, 
methane is not always present in the colon nor is it always present in expired air, 
consistent with inter-human variability in colonic environment (McKay, 1985; 
Nakamura, 2010). In North America, it is estimated that approximately 33% (Bond, 
1971) to 58% (Pitt 1980) of the healthy adult population produce methane in their 
gut. Though production is variable from person to person, in those who do 
demonstrate methanogenic activity it has been established that methane production 
is not affected by eating or fasting phases (Bond, 1971).  
According to Pochart et al. (1992) it takes a methanogen density of >107-108 
CFU/g in order to reach the detection threshold in breath samples. They also state 
that most producers have about 109 CFU/g residing in their gut, and those who 
produce methane but not as evidenced by breath analysis have about 104 CFU/g in 
their gut. 
McKay et al. (1985) examined methane production in a large population of 
subjects, hospitalized for a wide variety of conditions involving altered 
gastrointestinal function. Additional control subjects were used who had been 
declared free of gastrointestinal disease by their family doctor. They found great 
variability in methanogenic activity, with diarrheal patients demonstrating results 
consistent with those with normal gastrointestinal function and Crohn’s, ulcerative 
colitis and pneumatosis cystoides intestinales patients demonstrating almost zero 
methane production amongst their subject pool. McKay et al. reflected on their 
findings in their discussion, and their conjecture is summarized as follows: They 
believe that when no significant methanogenic activity is recorded, influences may 
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have included rapid transit of intraluminal contents, alterations in epithelial integrity, 
interferences with methane absorption into the bloodstream and/or transportation 
to the lungs, and modifications in the physical structure of the colon. 
Pique et al. (1984) also confirmed with their findings that certain 
pathophysiological conditions within the gastrointestinal tract influence 
methanogenesis. They witnessed an increased production within a population 
diagnosed with pre-malignant polyps. However in their study with cancer patients, 
where they saw that 80-90% of them were methane producers compared to only 
40% of their controls, they credited the tumors as promoters of methane production. 
It is important to note the role of interspecies hydrogen transfer in 
methanogenic activity. Methanogens utilize carbon dioxide and hydrogen, 
byproducts of communal microbe-driven reactions, to produce methane and water 
(Levitt & Ingelfinger, 1968). Thus, methane producers may yield significantly 
different breath hydrogen concentrations – even lower than non-producers in some 
cases – due to the frequent and variable uptake of free hydrogen as they reduce 
carbon dioxide to methane (Levitt, 2006; van Munster, 1994).  
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CHAPTER 3  
METHODS 
Subjects 
Subjects were recruited from Arizona State University and the surrounding 
community. Sixteen healthy persons, three males and 12 females, were enrolled in 
this study. One female subject dropped out prior to any appointments involving data 
collection, for reasons unrelated to the study. The remaining 15 subjects met 
enrollment criteria for age, 20-60 years (30±10.2; mean ± standard error). Waist 
circumference was measured at the initial assessment appointment (32.7±4.9 and 
33.1±2.3 for women and men, respectively). As per inclusion criteria, all 15 subjects 
had no prior history of gastrointestinal (GI) disease or resections impacting normal 
GI function, were non-smokers, were non-vegetarian/vegan, were not taking any 
medications known to alter (glucose) metabolism, and were free of chronic disease 
including diabetes. All subjects were screened using a medical history questionnaire 
(Appendix D) during the initial assessment appointment, also during which time 
informed written consent (Appendix C) was obtained to proceed with testing 
procedures, which included consuming test meals and providing blood and breath 
samples at various intervals throughout each of two, 3.5-hour long trial visits one 
week apart. The Arizona State University Institutional Review Board, Human 
Subjects Committee approved this research project prior to recruitment (Appendix 
C).  
Study Design 
 The study was comprised of two trial visits, during which each subject was 
required to stay onsite for approximately 3.5 hours. There was a preload component 
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to be completed by the subjects on their own the day prior to each of their trial 
visits. The study was conducted over a two week period (one trial per week per 
subject) allowing a one-week washout period as subjects were to consume both the 
placebo and the treatment in this randomized, double-blinded crossover study. 
Preload 
Subjects were to record food and beverage intake as well as the time of 
consumption from the point of waking the day before the study until 10:00pm that 
night, after which point they were told not to ingest anything except water until they 
arrived at the testing facility (Arizona Biomedical Collaborative building 1) the next 
morning. The dinner meal they were to consume was a standardized, Subway® meal 
which, in addition to the 6-inch submarine sandwich, included a sugar-containing 
soft drink of choice and a cookie (see Table 1 for meal composition and nutrition 
information). Subjects were also told to abstain from moderate to vigorous physical 
activity in the 24 hours prior to each of their visits. 
Trials 
Subjects arrived fasted at their appointments and underwent baseline testing, 
which included a venous blood draw for serum insulin analysis, a finger prick for 
capillary blood glucose analysis, and a breath collection for hydrogen, methane and 
CO2 concentrations. After these three samples were collected they were given either 
the placebo or the ACV to drink (depending on the randomization schedule; see 
Table 2) followed by the standardized high-carbohydrate meal (1 plain white bagel 
with 20g butter, and 200mL juice = 100g carbohydrate). See Tables 3 and 4 for 
detailed composition of the meal and the drinks, respectively. The time at which the 
subject finished the meal was recorded. One more venous blood sample was taken at 
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30 min (postprandial), three more breath samples were collected at 60, 90 and 180 
min, and six more finger sticks were conducted at 30, 60, 90, 120, 150 and 180 min. 
All results were immediate and thus recorded during each visit except for insulin, 
which was measured at the end of this study by radioimmunoassay. The subjects 
were not allowed to consume additional food or beverage with the exception of 
water until after their last sample was collected at 180 min, at which point they could 
leave the test site and were free to resume their normal activities and dietary 
behaviors. 
Anthropometric Measurements 
 Values for body weight, height and waist circumference were obtained for 
each of the 15 subjects during their initial assessment appointment (Table 5), which 
took place anywhere from 4 weeks to 1 day prior to their first trial visit. Height was 
measured at standing position (with feet and head coverings absent) using a 
stadiometer (seca Corporation, Chino, CA), and was recorded in inches (in). Waist 
circumference was obtained by a spring-adjusted tape measure (Country Tech, Inc., 
Gays Mills, WI) placed at the level of the umbilicus, and was recorded in inches (in). 
Body weight was obtained by a bioelectrical impedance analysis scale (TANITA 
Corporation of America, Inc., Arlington Heights, IL), with the subject wearing 
light/exercise clothing, and was recorded in pounds (lbs).  
Food Analysis 
 Apple cider vinegar was obtained from H.J. Heinz Company, L.C. 
(Pittsburgh, PA). The amount administered in each serving was determined based on 
the amounts used in other studies with a similar study design (Johnston, 2004). 
Subway® meal nutrient analysis was provided by Subway, Inc. (Table 1).   
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Blood Analysis 
 A trained phlebotomist conducted all blood draws. Blood was collected into 
a red top tube with a clot activator for insulin analysis. The red top tube was left at 
room temperature for approximately 25 minutes to clot and then spun for 15 
minutes in a centrifuge set at 3000 rpms. Serum was removed and frozen at –80° 
until thawed for analysis, which was conducted at the Polytechnic Campus of 
Arizona State University (Mesa, AZ) via radioimmunoassay (Millipore Corporation, 
Billerica MA). Finger pricks for capillary blood glucose values were conducted by 
individuals who successfully completed BioSafety Training (CITI Program, 
University of Miami, FL). Accu-Chek glucometers were used (Roche Diagnostics, 
Indianapolis IN) and each subject had their own glucometer for the duration of each 
trial visit.  
Breath Analysis 
 Breath hydrogen, methane and CO2 were determined using a BreathTracker 
SC (QuinTron Instuments, Inc., Milwaukee, WI) instrument. End-expiratory alveolar 
breath samples were collected via bag and syringe and then injected into the machine 
for analysis by three gas solid-state detection. Results were recorded as the corrected 
value. According to the QuinTron Instrument Company, their “correction factor” is 
based on the assumption that alveolar CO2 concentration is a constant value 
(40mmHg) and atmospheric CO2 has a concentration of nearly zero. Thus if the 
sample was contaminated with room air, the CO2 concentration in the sample will be 
reduced. Therefore, the following formula is utilized by the machine to estimate the 
correction factor, which is subsequently multiplied by each raw value to get the final, 
corrected values of H2 and CH4: 
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FACTOR = ALVEOLAR CO2 CONCENTRATION / SAMPLE CO2 
CONCENTRATION 
Statistical Analysis 
 Statistical analysis was carried out using the Statistical Package for Social 
Sciences (SPSS) version 19 (SPSS, Inc., Chicago, IL). Repeated measures analysis of 
variance (ANOVA) and paired-samples t-tests were used to analyze the data 
collected in this study, with a p-value for significance set at less than 0.05. Results are 
reported for individual variables as the mean and standard error (SEM). 
  
Table 1 
 
Subway Meal Composition. 
 
 
 
Table 2 
 
Subjects’ Randomization Schedule. 
 
 
 
 
 
 
 
 
  
Food Item Amount  Kcal  CHO  Fat  Protein  
Sweet Onion Chicken 
Sandwich 
6 inch 380 59g 4.5g 26g 
Soft Drink 16 fl oz, plus ice 210 52g 0g 0g 
Subway Choc. Chip Cookie 1 whole 210 30g 10g 2g 
Visit # 1 Visit #2 
Treatment Subject #  Treatment Subject #  
Vinegar 2,6,11,14,9,13,8 Vinegar 3,5,10,7,4,16,12,1 
Placebo 3,5,10,7,4,16,12,1 Placebo 2,6,11,14,9,13,8 
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Table 3   
 
High Glycemic Index (GI) Test Meal Composition.  
 
 Svg size Calories Carbohydrate Fat Protein 
Bagel 4oz 300 60g (5g sugar, 2g fiber) 1g 12g 
Butter 20g 85 0g 10g 0g 
Juice 200mL 90 22g 0g 0g 
TOTAL  475 82g 11g 12g 
 
 
Table 4 
 
Test Drink Composition. 
 
Placebo Vinegar 
60g water 40g water 
2.5g Sweet’n Low 20g apple cider vinegar 
1 drop green food coloring 2.5g Sweet’n Low 
 1 drop green food coloring 
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CHAPTER 4 
RESULTS 
Descriptive Characteristics 
 Fifteen subjects (4 males and 11 females) participated in this study that 
examined the effects of vinegar on postprandial glycemia and insulinemia as well as 
the effects on breath hydrogen concentration in normal glucose-tolerant individuals. 
Five subjects were Hispanic and the remaining 10 were White/Caucasian. Out of 185 
individuals who volunteered to take the initial survey (Appendix B) 72 did not qualify 
for the study based on their response set, 97 individuals did qualify based on their 
response set however they did not express interest in pursuing the study, and 16 
subjects gave written consent to pursue the study (Appendix C). The sixteenth 
subject who was recruited dropped out prior to any data collection due to reasons 
unrelated to this study. Data were successfully collected from 15 subjects without 
major difficulty or disruption; test meals were fully consumed by all subjects and no 
substitutions were allowed. Table 5 outlines descriptive characteristics of the 15 
subjects participating in this study. Table 6 displays all baseline measurements taken 
at 0 min for both the control and vinegar trials, as well as a column dedicated to the 
merged data (mean ± SEM), as the preparation and settings were virtually identical in 
both cases.  
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Table 5  
Descriptive Characteristics of Study Subjects (n=15).1 
Gender (M/F) Age (y) Height (in) Weight (lbs) Waist (in) BMI % Body Fat 
Male (4) 23.8 ± 1.7 67.3 ± 2 157 ± 17.9 33.1 ± 1.2 24.2 ± 1.3 18.8 ± 1.1 
Female (11) 32.8 ± 3.3 64.2 ± 0.9 150.5 ± 9.5 32.7 ± 1.5 25.8 ± 1.6 31.5 ± 3.2 
1All data are recorded as the mean ± SEM. 
 
Table 6  
Baseline Data for Study Subjects (n=15).1 
  Control Vinegar   p-value Combined2 
Reference 
(Normal) 
Fasting Glucose (mg/dL) 97.1 ± 1.9 94.5 ± 1.4 0.119 95.8 ± 1.2 70-105 
Fasting Insulin (mU/mL) 13.5 ± 1.8 14.6 ± 2 0.432 14.8 ± 1.3 6-24 
Baseline Breath H2 (ppm) 11.8 ± 4.0 9.5 ± 2.8 0.509 10.7 ± 2.4 0-10 
Baseline Breath CH4 (ppm) 10 ± 4.7 9 ± 4.2 0.749 7.7 ± 2.7 
 1Data are recorded as the mean ± SEM.  
2Merged data represented as “Combined”. 
3Values obtained from Tietz, et al., 1987. 
4Values obtained from Eisenmann, et al., 2008. 
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Postprandial Insulin and Glucose Response 
 Insulin and glucose concentrations in blood were normally distributed at all 
time points. Venous blood was drawn at 0 and 30 min for analysis of subject insulin 
levels for both baseline and postprandial. No statistical difference was detected for 
the time-by-treatment interaction (repeated measures ANOVA; p=0.818) between 
the control and vinegar treatments for postprandial serum insulin concentrations, 
indicating no significant change in insulin sensitivity associated with treatment (Table 
7, Figure 1).  
Finger sticks were performed to determine incremental capillary glucose 
concentration at 0, 30, 60, 90, 120, 150, and 180 min in both treatments. Repeated 
measures ANOVA revealed a significant time-by-treatment interaction (p=0.001; 
effect size = 0.878). Paired samples analysis showed statistically significant 
differences (p<0.05) in the mean values of each treatment at 30, 60 and 180 min 
(Table 7, Figure 2). Vinegar consumption was associated with a significantly lower 
blood glucose concentration at 30 (p=0.003) and 60 (p=0.005) min than that for the 
control treatment. At 180 min vinegar treatment was associated with a significantly 
greater blood glucose concentration (p=0.045) and it important to note the similarity 
of these values to those measured at 0 min. This part of the analysis suggests 
prolonged return to baseline blood glucose concentrations is associated with vinegar 
consumption. 
  
Table 7 
Repeated Measures ANOVA for Blood Glucose Concentrations and Serum Insulin Concentrations.1  
1Data includes both experimental conditions and values are reported as the mean ± SEM.  
*Difference in means is significant; p<0.05.
Glucose (mg/dL) 0 min 30 min* 60 min* 90 min 120 min 150 min 180 min* p-value Effect sz 
control 97.1 ± 1.9 141± 5.2 124.2±6.2 114.4±4.1 105.7±2.3 101.3±2.5 91±1.9 
0.001 0.878 vinegar 94.5 ± 1.4 120.2±3.9 111.8±3.8 110.7±4.5 101.7±2.9 99.3±2.8 94.7±2.1 
Insulin (mU/mL) 0 min 30 min p-value Effect sz 
     control 13.5±1.8 73.6±10.2 
0.818 0.004      vinegar 14.6±2 77.4±12.2 
     6
0
 
  
 
Figure 1.  Postprandial serum insulin after the high-starch 
meal under both experimental conditions: control, 
vinegar. No significant difference was noted between 
treatments (p>0.05). 
 
  
  
 
Figure 2.  Postprandial blood glucose concentrations after 
the high-starch meal under both experimental conditions: 
control, vinegar. All data are given as the mean ± SEM.  
*Represents significant difference between treatments as 
indicated by a paired t-test; p<0.05.
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Postprandial Breath Hydrogen   
Data from breath hydrogen analysis were not normally distributed. Table 8 
provides data reported as the mean ± SEM for both treatments. Baseline data (0 
min) were out of permissible range (measurements > 10ppm fasting; Eisenmann, 
2008) and were excluded from analysis. Data collected at 60 and 120 min fail to 
reach the minimum threshold value to be considered reflective of true malabsorption 
(measurements < 20ppm; Eisenmann, 2008) and were also excluded. Only data from 
180 min were considered for further analysis for the purpose of denoting a trend 
associated with vinegar consumption and increased breath hydrogen over time. A 
non-parametric t-test showed p=0.066 (Figure 3).  
 
Table 8  
 
Breath Hydrogen Concentrations Over Time.1  
1Data recorded as mean ± SEM. 
2Baseline (0 min), 60 min, 120 min data out of permissible range – excluded from 
analysis (Eisenmann 2008). 
3p-value represents data for 180 min only.  
Hydrogen (ppm) 2 0 min 60 min 120 min 180 min p-value3 
Control 11.8±4 5.133±1.2 2.8±0.5 2.1±0.4 
 Vinegar 9.5±2.9 5.2±1.0 2.9±0.7 3.7±1.1 0.066
 63 
  
Figure 3.  Postprandial breath hydrogen after the high-starch meal under both 
experimental conditions: control, vinegar. No significant difference was noted 
between treatments (p>0.05).  
♯Represents statistical trend in difference between treatments as indicated by non-
parametric t-test; p=0.066. 
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CHAPTER 5  
DISCUSSION 
 Attenuation of the glycemic response to a high-starch meal as a result of 
preprandial vinegar ingestion has been demonstrated in both glucose-tolerant 
(Ostman, 2005; Johnston, 2010) and insulin-resistant (Johnston 2004) populations. 
The present study was able to reproduce these findings in healthy, normal glucose-
tolerant subjects. Vinegar treatment significantly reduced the mean blood glucose 
concentrations at 30 (p=0.003) and 60 min (p=0.005) post meal compared to the 
control values; furthermore, vinegar treatment prevented the slight dip in glucose 
concentrations noted in the control group at 180 min (p=0.045), thereby sustaining 
blood glucose concentrations over time (Table 7, Figure 2). These data suggest that 
vinegar has the ability to buffer the rise in blood glucose after a high-starch meal and 
moderate the return to baseline. The effect is similar to that observed with the use of 
prescription antihyperglycemic drugs such as metformin and acarbose (Inzucchi, 
2002; Chiasson, 1996; Bailey, 1992). Although postprandial glycemia was not the 
focus of this research, these data enhanced the credibility of vinegar as an 
antiglycemic agent and verified the antiglycemic activity of vinegar during 
simultaneous collection of breath hydrogen. 
 There are no studies to our knowledge that have been conducted using 
breath hydrogen testing to measure colonic fermentation in response to vinegar 
ingestion prior to a high-starch breakfast meal. Previous studies have incorporated 
the use of breath hydrogen testing to measure colonic fermentation in response to 
high-fiber diets (Muir, 1995), for diagnosing gastrointestinal disorders (Simren & 
Stotzer, 2006), and in demonstrating the effects of certain medications, such as 
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antibiotics (Gilat, 1978) and biguanides (Arvanitakis, 1974), as well as supplements, 
such as lactulose (Levitt, 1968; 1969). The present study targeted the effects of 
vinegar ingestion on postprandial colonic fermentation as determined by the breath 
hydrogen testing method, to better understand the mechanism by which vinegar acts 
as an antiglycemic agent. The results did not show any significant difference in 
hydrogen production between vinegar and control treatments from baseline through 
180 min postprandial, nor did the results show significant increases over baseline to 
indicate malabsorption at any point through 180 min. 
It has been proposed that vinegar may inhibit disaccharidase activity (Ogawa, 
2000) that would otherwise be responsible for the digestive task of breaking down 
starch into its absorbable state as individual glucose molecules. By doing so the 
ingested vinegar would partially prevent high-starch foods from being processed and 
absorbed; instead incompletely digested polysaccharide chains would travel through 
to the colon, providing resident bacteria with substrate for fermentation. An 
increased postprandial production of hydrogen, the by-product of colonic 
fermentation of resistant starch, as a result of co-ingested vinegar was hypothesized 
in the present study. 
In trying to explain the lack of hydrogen production, possible limitations of 
this study must be considered. Subject compliance and adherence to directions for 
standardized preparation prior to each day of their trials may not have occurred. 
Subjects were told to abstain from vigorous exercise for 24 hours, to consume a 
standardized, high-carbohydrate meal the evening prior to each of their two trials 
(vinegar and control; crossover design with one week washout), and to arrive to the 
lab on the morning of their study in a fasted state having only the option to consume 
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plain water. Withholding exercise 24 hours prior to testing and consuming a high-
carbohydrate meal the evening before should ensure that the subjects’ muscle 
glycogen stores are fully saturated, to prevent the incidence of enhanced uptake of 
glucose into the muscle after the subjects ate their standardized breakfast meal in the 
lab (National Institutes of Health Clinical Center, 1999). This would alter testing 
results due to metabolic compensation mechanisms increasing the rate of starch 
digestion and absorption for glycogen repletion. Even though subjects verified their 
fasted state upon arrival to the lab on the morning of their trials and food intake on 
the day prior was recorded, collected and reviewed the possibility remains that 
subjects did not follow these preparatory guidelines. 
Another likely limitation became apparent after the data had been collected: 
the knowledge that unclean teeth prior to breath analysis can be a hindrance to 
sample analysis. Eisenmann et al. (2008) reported that residual bacteria in the mouth 
may produce a false positive result, as these bacteria may add hydrogen gas to the 
collection sample which would otherwise only reflect colon fermentation status. 
Muir et al. (1995) also recommended the use of mouthwash prior to breath sampling 
in their study. The mean data from the present study suggest that residual oral 
bacteria may have augmented the baseline testing results in both treatments (Table 8, 
Figure 3). Had this scheme been identified prior to the commencement of the 
present research study it would have been incorporated into the protocol and all 
subjects would have been required to brush their teeth upon rising and to rinse their 
mouths prior to baseline breath collection. Subsequent studies of similar 
methodology to the present study should feature the use of mouthwash before 
baseline breath sampling. 
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In attempting to explain the lack of rise in breath hydrogen over time, which 
was hypothesized to occur with vinegar treatment, at least three possible factors 
must be considered. The first would be that there was no significant rise in breath 
hydrogen due to the limited timeframe during which breath samples were collected 
and analyzed. It is important to note the observation of the statistical trend for 
increasing breath hydrogen concentrations from 120-180 min postprandial with the 
vinegar treatment (p=0.066; Table 8), as this may be an indication of further increase 
in colonic fermentation over time beyond 180 min. Therefore, while the results of 
this study may have reflected an unchanged colonic environment from baseline to 
180 min postprandial, the potential may exist for significant changes (p<0.05) 
associated with the vinegar treatment beyond 180 min. In a similar study examining 
colonic fermentation as a corollary to high-fiber diets (Muir, 1995) the researchers 
observed breath hydrogen concentrations from subject sampling through 27 hours in 
order to determine significance. The present study protocol, using 180 min as the 
endpoint for data collection, was designed in a comparable manner to studies using 
lactulose as the malabsorbed agent, which passes rapidly through the gastrointestinal 
tract (Caride, 1984). However, in an earlier study that systematically investigated the 
validity of the lactulose hydrogen breath test to set up a reference standard to which 
other carbohydrate malabsorption testing may be compared, Rumessen et al. (1989) 
analyzed breath samples over the course of 12 hours. Thus, subsequent studies of 
similar methodology to the present study should feature a prolonged sampling period 
to encompass a more appropriately scaled data set. 
A second factor to consider is that the dose of vinegar ingested by the 
subjects was not sufficient enough to cause bacterial fermentation to reach detectable 
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threshold, and what was seen within the data was reflective of normal colonic 
activity. According to several studies, the threshold at which a substance is 
considered to have caused a significant disturbance within the colonic environment 
is a breath hydrogen concentration of ≥20ppm. The data collected from the present 
study show mean values below 5ppm at 60, 120, and 180 min postprandial with both 
treatments. A third possibility is that the degree to which vinegar demonstrates an 
inhibitory effect on disaccharidase activity to reduce absorption of starch, regardless 
of dosage, does not affect activity of colonic bacteria to the same extent as innately 
malabsorbed materials such as fiber (Muir, 1995) and lactulose (Maung, 1992).  
It is also important to note that a significant portion of the high-
carbohydrate breakfast meal consisted of monosaccharides in the form of fruit juice 
offered as a part of the meal. Monosaccharides are the most basic form of 
carbohydrate, and are readily absorbed from the bloodstream. Thus, without any 
need for disaccharidases to break down this type of carbohydrate there is less of a 
basis provided upon which the vinegar may act in demonstrating the hypothesized 
antiglyemic effects. It is recommended that for subsequent studies of similar 
methodology to the present study, only food and beverage items in the form of 
complex carbohydrate (polysaccharides) should be used in the test meal. For 
example, the substitution of a milk product (cow or almond) for juice would be 
feasible since these items contain lactose or polysaccharides (almond milk contains 
tapioca starch) that would require digestion prior to absorption (Tester, 2004).   
With the failure of the data to support the premise that vinegar causes dietary 
starch to pass through the gastrointestinal tract unabsorbed in a similar manner as 
observed with other malabsorbed materials, one should attempt to justify alternative 
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mechanisms by which vinegar attenuates postprandial glycemia. There is evidence in 
other literature suggesting that vinegar slows gastric emptying rates (Hunt, 1969; 
Liljeberg & Bjorck, 1998), and still more evidence suggesting that vinegar may 
enhance cellular uptake of glucose from a meal (Fushimi, 2001; 2002). Both 
mechanisms work independently to attenuate postprandial extracellular blood 
glucose concentrations. Serum insulin was another parameter that was measured in 
both treatments. Previous studies support the association of vinegar consumption 
and enhanced whole-body insulin sensitivity, promoting increased insulin action for 
the removal of glucose from the bloodstream (Ostman, 2005). However, the mean 
values for both vinegar and control trials in the present study were not significantly 
different. It is reasonable to expect this outcome due to the fact that all subjects were 
normal, glucose-tolerant individuals with no prior history of prediabetes or insulin 
resistance and a BMI of 25.3±1.2 (mean ± SEM). It is difficult to effect an 
improvement in a parameter that is already within normal limits. 
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CHAPTER 6 
CONCLUSION 
 In summary, the results of the present study fail to support the first 
hypothesis. Both vinegar and placebo treatments failed to produce an increase in 
postprandial breath hydrogen concentrations. Since proper preparatory measures 
may not have been utilized to eliminate confounding factors, such as the presence of 
oral bacteria, baseline data was excluded from analysis. Beyond this, remaining data 
showed no significant increase in colonic fermentation over time with either 
treatment. In light of previous studies using a longer data collection period, an 
upward trend in mean breath hydrogen concentration from 120 min to 180 min 
observed with the vinegar treatment in the present study suggests that there may 
have been significant findings had the data collection been extended over several 
more hours. 
 The second hypothesis was halfway supported by the significant reduction in 
postprandial blood glucose seen with vinegar treatment as compared to placebo; 
however postprandial insulin values were unchanged with vinegar, as no significant 
difference existed between the two treatments. Because the subjects used in the 
present study were healthy, glucose-tolerant individuals under the age of 60, it is a 
reasonable expectation that insulin sensitivity may not vary greatly from one 
treatment to the next in a population whose insulin sensitivity is already within 
normal limits. 
 Due to its proven ability to attenuate the rise in blood glucose levels after a 
high-starch meal in glucose-tolerant and insulin resistant individuals as well as those 
with type 2 DM, vinegar deserves much more praise and attention, and even 
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accreditation for use in treating and controlling glycemia. From a healthcare 
standpoint, vinegar is much more conventional than pharmaceutical interventions 
due to its widespread availability and low cost. 
 It remains unclear whether vinegar inhibits disaccharidase activity to 
attenuate the glycemic response after a high-starch meal. The present study did not 
validate this proposed mechanism of action. More research is warranted using 
different techniques to assess inhibition of disaccharidase activity. However, other 
possible mechanisms that exist have been described elsewhere in the literature and 
must be considered as well. 
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APPENDIX A 
RECRUITING ADVERTISEMENT 
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Volunteers Needed for Breath Hydrogen Trial 
The Nutrition Program is recruiting adults for a research trial.  The study 
will test how a natural drink will alter breath hydrogen, an indicator of colon 
health.  Participation in this study is voluntary. Participants will receive test 
foods and $40 in Target gift cards during the study. 
We are recruiting individuals who are healthy (20-60 years of age), who do 
not have diabetes or chronic disease, who are willing to provide breath 
and blood samples, and who are not vegetarians.   
For more information or to apply for the study, please visit our recruitment site: 
https://www.surveymonkey.com/s/asu_breathH2 
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APPENDIX B 
PRE-ENROLLMENT SURVEY
 86 
Generated and implemented using SurveyMonkey®. 
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APPENDIX C 
INSTITUTIONAL REVIEW BOARD APPROVAL AND CONSENT FORM 
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APPENDIX D 
MEDICAL HISTORY QUESTIONNAIRE 
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APPENDIX E 
GENERAL STUDY INSTRUCTIONS
 96 
Breath Hydrogen Study Instructions 
 
Thank you for participating in this study.  This sheet contains some important 
information regarding the study.  Please feel free to email/call Emily if you have any 
questions. (email: emedved@asu.edu, phone: 510-599-1169)  
 
Day Prior to the Study 
 Do not engage in any intense physical exercise (light walking, household 
chores, etc. are OK) 
 Log foods and beverages eaten from the time you wake until the time 
you go to sleep (see Food Log) 
 Eat a Subway dinner (see Subway Dinner Guide) no later than 10:00pm 
 Refrain from eating 10 hours prior to your scheduled visit 
 
Day of your Appointment 
 Do not eat or drink anything, and do not chew gum 
 Report to the testing facility fasted for your scheduled appointment 
 All appointments will be held in the Arizona Biomedical Collaborative 1 
(5th St. and Van Buren, downtown Phoenix). Metered street parking is 
available. Call Emily once you have arrived and one of the staff will guide 
you to the lab. 
 
Study Appointments 
Trial 1 Appointment: _______________________________________ 
Trial 2 Appointment: _______________________________________ 
 
 97 
APPENDIX F 
FOOD LOG AND INSTRUCTIONS
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APPENDIX G 
SUBWAY MEAL GUIDE AND INSTRUCTIONS 
 
 100 
Subway Meal Guide 
 
Please use the gift card provided in your folder to purchase your 
dinner at Subway the night before your trial appointments. Each 
voucher is valued at $8.00, which is enough to purchase one meal 
deal. To locate the Subway restaurant nearest you, please visit 
http://www.subway.com/storelocator/.  
 
Please order one 6-inch Sweet Onion Chicken Teriyaki sandwich 
MEAL (to come with drink and cookie – see below) 
Specifications when ordering the sandwich:  
 White bread 
 No cheese 
 Any vegetable topping of your choice 
 Sweet Onion sauce  (no oil, vinegar or dressings) 
Specifications when ordering the cookie: 
 Chocolate chip cookie 
Specifications for the fountain drink: 
 Any regular soda (no “diet” or “light” options, no tea, no 
water) – Sprite, Dr. Pepper, Root Beer, Pepsi/Coke are OK 
 
If you have any questions, please do not hesitate to email/call Emily 
at emedved@asu.edu/510-599-1169 at any time! 
